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Abstract 
Purpose:  Oxidative post-translational modification of protein-bound tyrosine residues can have 
a significant impact on protein structure and function and thus may be important to physiological 
and pathological processes.  Oxidative stress has been correlated with biological aging and many 
disease states, including diabetes, atherosclerosis, and neurodegeneration.  Proteomic methods 
targeted to these modifications are important tools for determining which specific modifications 
may be significant in these conditions.  Toward this end, a method designed to fluorogenically 
label the protein oxidation products 3-nitrotyrosine (3NY) and 3,4-dihydroxyphenylalanine 
(DOPA) using benzylamine-dependent chemistry is applied to model peptides and proteins, as 
well as cardiac tissue samples from a rat model for aging. 
Methods:  Peptides or proteins are reacted with excess benzylamine (or a derivative thereof), in 
the presence of potassium ferricyanide, to fluorescently label DOPA residues by forming 2-
phenylbenzoxazole derivatives.  To label 3NY residues, the peptides or proteins are first reduced 
with sodium dithionite to give 3-aminotyrosine, which can undergo a similar reaction with 
benzylamine and oxidant to give the same products.  Products are characterized by fluorescence 
spectroscopy, high-performance liquid chromatography (HPLC) with UV and fluorescence 
detection, mass spectrometry, and amino acid analysis.  For enrichment by boronate-affinity 
HPLC, the benzylamine derivative (3R, 4S)-1-(4-(aminomethyl)phenylsulfonyl) pyrrolidine-3,4-
diol (APPD) is used as the tagging reagent. 
Results:  Cardiac proteins have been fluorescently labeled and separated, and some putative 
identifications have been made.  A model protein, glycogen phosphorylase b (Ph-b), has been 
nitrated in vitro and labeled within a matrix of cardiac homogenate, and the products exhibit 
concentration-dependent fluorescence.  The loss of 3NY from nitrated Ph-b upon mixing with 
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cardiac homogenate has been observed and examined.  Five model peptides have been labeled 
with APPD to determine the effect of primary structure on labeling efficiency, fluorescence 
quantum yield, and molar absorptivity. 
Conclusions: This method has great potential to aid identification of the protein oxidation 
products DOPA and 3NY in proteomic studies of tissue samples and can also be adapted for 
affinity enrichment and relative quantification of these low-abundance species. 
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Chapter 1: Introduction to Oxidative Post-Translational Modifications of 
Protein-Bound Tyrosine Residues
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1.1 Tyrosine Modifications in Aging 
 This section has previously been published as a review article (22). 
1.1.1 Introduction 
 Various oxidative post-translational modifications (PTMs) of proteins accumulate in cells 
during aging and disease, particularly age-related diseases such as atherosclerosis, cataracts, type 
2 diabetes, and neurodegenerative diseases.  Such modifications can alter protein structure and 
function by inducing conformational changes, partial or complete unfolding, cross-linking, 
and/or aggregation, or by modifying enzyme active st s, phosphorylation sites, or binding sites.  
These modifications can lead to either gain or lossof function and may serve 
physiological/regulatory purposes or contribute to (or at least accompany) pathogenesis [see 
(52,67,81) and references cited therein]. 
Modifications of Tyrosine 
Protein Tyr residues are susceptible to an array of oxidative and nitrative modifications 
(Fig. 1), including the formation of 3-nitrotyrosine (3NY), which may be reduced to 3-
aminotyrosine (2,78); 3,4-dihydroxyphenylalanine (DOPA); 3,3’-dityrosine (DiY); 3-
chlorotyrosine (3ClY); 3,5-dichlorotyrosine (DiClY); as well as brominated and iodinated forms 
(11,67,81).  Further oxidation can convert DOPA to dopaquinone (DQ) or 3-aminotyrosine to the 
quinone imine, representing acceptors for conjugate additions.  Subsequently, protein-bound DQ 
and quinone imine may propagate oxidative damage to DNA and lipids, as well as other proteins 
(54).  Additionally, ortho-tyrosine (2-hydroxyphenylalanine, o-Tyr) and meta-tyrosine (3-
hydroxyphenylalanine, m-Tyr) are products of reaction between hydroxyl radic ls (or their 
metal-bound equivalents) and Phe [(52,67,81) and references cited therein].  While mostly non-
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enzymatic, all of these modifications can preferentially accumulate on specific proteins, as well 
as specific residues within those proteins (2,52,67). 
 
Fig. 1.  Endogenous post-translational modifications of protein-bound Tyr.  EPO: eosinophil 
peroxidase; MPO: myeloperoxidase; TPO: thyroid peroxidase. 
Consequences of Modification 
 In many cases, oxidation targets proteins for degradation, perhaps due to the increased 
surface hydrophobicity that results from unfolding or misfolding (13,19,67,81).  However, after 
extensive oxidative modification and/or when cross-links and aggregates form, proteins can 
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become resistant to and even inhibit proteolysis, leading to pathological accumulation and 
deposition (13,19,81).  Proteolysis by both proteasomal and lysosomal pathways also tends to 
decline with aging and certain disease states, which may further contribute to cellular senescence 
and to pathologies characterized by protein deposition, such as atherosclerosis, cataract, macular 
degeneration, rheumatoid arthritis,  and neurodegenrative diseases like Alzheimer’s disease 
(AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) (13,19,36,67,81). 
The introduction of modified residues within proteins and any associated structural 
changes can create neo-epitopes for antibody recognition, and cross-reactivity with unmodified 
self-proteins can induce autoimmune disorders.  This is particularly relevant for modified 
proteins that are absent during early development but accumulate with age (2,52,67). 
 In addition to these general consequences for proteins, oxidation can have specific effects 
on the function of a particular protein.  For example, it can modify an active site, block a 
phosphorylation site, or disrupt a binding site for substrates, cofactors or partner proteins.  If a 
particular modification is reversible by either repair or protein turnover, it may serve a regulatory 
function and/or participate in cellular signaling pathways [(2,52,67) and references cited therein]. 
Importance of Site Specificity 
While overall levels of a particular Tyr modification (e.g. protein-bound 3NY or DOPA) 
may or may not be measurably elevated in a particular tissue or cell sample, specific proteins 
may carry significant levels of such modifications (52,67).  When these proteins are of low 
abundance, the absolute quantity of the modification will not contribute significantly to the 
overall yield in the sample.  Nevertheless, the modification may be physiologically important.  
For this reason, many proteomic studies have been undertaken to identify long lists of Tyr-
modified proteins.  However, the focus of the present r view will be on progress made in 
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characterizing the effects of specific protein modifications on structure, function, aggregation, 
and pathogenesis, with an emphasis on implications f r aging.  The discussion will concentrate 
on studies published over the last 5 years. 
1.1.2 3-Nitrotyrosine 
Formation and Significance 
 3NY is the most commonly measured Tyr oxidation product, due to its relative chemical 
stability, the availability of anti-3NY antibodies, and its status as a marker of nitric oxide (NO)-
dependent protein modifications.  3NY is generated by several pathways, including reactions of 
peroxynitrite (ONOO−) or nitrogen dioxide (•NO2)
 and catalysis by heme-containing proteins 
(52,67). The nitration of Tyr can lead to conformational changes, unfolding, aggregation, 
immunogenicity, and/or partial or total inactivation f a target protein, although in some cases 
gain of function has been observed.  These consequences may be attributed to changes in steric 
requirements, electrostatics, pKa of amino acid side chains, and/or surface hydrophobicity.  
Going beyond tables of proteomic identifications, there have been significant developments in 
the study of specific protein nitration sites and their effects on structure and function.  The 
possibility of 3NY as a signaling moiety has also been proposed, and evidence has been 
presented for pathological roles of 3NY-containing proteins.  For a comprehensive review, see 
(52) and references cited therein. 
Inactivation of MnSOD by Nitration of Tyr-34 in the Active Site 
 The activity of human manganese superoxide dismutase (MnSOD), which  protects cells 
from damage by scavenging superoxide, is largely inhib ted by nitration at Tyr-34 in the active 
site, and this modification has been observed in agi g, ALS, AD, PD, and diabetes, among others 
(42,52).  Quint et al. (61) determined the crystal structures of both native and nitrated enzyme in 
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order to investigate the mechanism of this inactivation (Fig. 2).  Treatment with peroxynitrite 
gave 75% yield of 3NY-34 and reduced enzymatic activity to 20% ± 5% compared to that of the 
wild-type enzyme.  Although mass spectrometry identifi d additional modification sites, 3NY-34 
was the only modification present in the crystal structure.  While no significant conformational  
 
Fig. 2.  Active site of native (a) and nitrated (b) human MnSOD, shown with Mn and its 
ligands, His-26, Tyr-34, His-74, Asp-159, and His-163.  Image derived from crystal structures 
stored in the Protein Data Bank (61); accession codes 2ADQ for native and 2ADP for nitrated.  
Figure generated using Protein Workshop (45). 
changes were evident upon nitration, enzyme inhibition was attributed to steric interference with 
substrate binding and changes in the hydrogen bonding network.  Electrostatic changes due to 
the lower phenolic pKa of 3NY relative to Tyr may also alter the finely-tuned redox potential in 
the active site and/or cause repulsion of the substrate, O2
•−, although this hypothesis was not 
tested.  The pKa of 3NY-34 in MnSOD is expected to be similar to that measured 
spectroscopically for 3NY-34 of the bacterial iron superoxide dismutase enzyme (FeSOD), 
which is 7.95, or approximately two units lower than that of Tyr [(61) and references cited 
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therein].  In this protein environment, this value is higher than the pKa ~7.2 measured for 3NY in 
other peptides and proteins and in its free form (78,91). 
 In order to isolate 3NY-34 from all other modifications that can occur with oxidizing 
agents, Neumann et al. (48) used a genetic approach for site-specific incorporation of the 
unnatural amino acid 3NY at position 34 in recombinant rat mitochondrial MnSOD.  Upon 
quantitative formation of this nitrated mutant, theenzyme showed 97% decrease in activity. 
Nitration Disrupts Catalysis by GAPDH 
 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a crucial protein for cellular 
metabolism and energy, is a common entry on proteomic lists of nitrated proteins, including 
studies of aging (33) and AD (82), likely due to its role as a sensor of NO (53).  In a mechanistic 
study, Palamalai et al. (53) recently determined that 
in-vitro nitration of Tyr-311 and Tyr-317 in rabbit 
GAPDH by tetranitromethane resulted in loss of 
binding to NAD+, thereby destroying all catalytic 
activity of the enzyme.  Computational analysis of 
the X-ray crystal structure predicted that these 
nitration sites are located very close to both the 
catalytic cysteine residue and the NAD+ binding 
site (Fig. 3).  Furthermore, in silico nitration 
resulted in an even shorter predicted distance (1.4 
Å) between 3NY-317 and NAD+, such that 
significant steric interference may occur.  
Alternatively, the movement of this residue at the 
Fig. 3.  Nitration sites of rabbit 
muscle GAPDH, Tyr-311 and Tyr-317, 
and their proximity to Cys-149 and 
NAD+ in the active site.  Image derived 
from the crystal structure stored in the 
Protein Data Bank (12); accession code 
1J0X.  Figure generated using Protein 
Workshop (45). 
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base of an α-helix may disrupt this secondary structure.  In fact, circular dichroism shows some 
loss of secondary structure following in vitro nitration. 
1.1.3 DOPA, DQ, and Tyr-Mediated Cross-links 
DOPA and DQ 
 Hydroxyl radicals can convert Tyr to DOPA (27), and site-specificity for this reaction can 
be facilitated by redox-active transition metals bound to proteins or by localized sources of 
hydroxyl radicals, such as mitochondria (46,95).  Through reversible oxidation to DQ, DOPA is 
part of a redox cycle capable of regenerating the reduced state of redox-active transition metals, 
particularly iron and copper, and of reducing metalloproteins (14,23,27).  This phenomenon can 
perpetuate oxidative insult but also presents an opportunity for putative signaling functions, such 
as triggering antioxidant defenses (46).  Protein-bound DOPA can also serve a protective role by 
scavenging radicals and chelating metals, although the latter function can alternatively direct 
oxidative damage to specific protein sites (46,47,80). 
DOPA and DQ can also be formed enzymatically by tyrosinase or tyrosine hydroxylase 
(54).  In addition, DOPA may be incorporated during protein synthesis when free DOPA is 
available to compete with Tyr, such as in levodopa-tre ted PD patients (18). 
Conjugate Addition 
DQ and the related quinone imine (e.g. an oxidation product of 3-aminotyrosine) can 
serve as conjugate acceptors for nucleophilic groups on other amino acid side chains to generate 
protein cross-links (54).  Protein aggregates may result that are resistant to proteolysis and can 
contribute to protein deposition/plaque formation in aging and various disease states (13,19).  
Conversely, such cross-links can perform important fu ctions.  For example, the cofactor lysine 
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tyrosylquinone is formed by the intramolecular addition of Lys-314 to the DQ moiety derived 
from Tyr-349 in lysyl oxidase (88). 
 
3,3’-Dityrosine 
 Another route to Tyr-mediated protein cross-links involves the combination of two 
tyrosyl radicals to form DiY (28,81).  Various pathways to the formation of tyrosyl radicals exist, 
mediated by hydroxyl radicals, peroxynitrite-derived species, peroxyl radicals, redox-active 
metals, γ-radiolysis, UV irradiation, heme, or hemeperoxidase enzymes (5,28,81).  In the 
hydrophobic region of biological membranes, lipid-derived radicals can also play an 
intermediary role (5).  Specificity may arise due to conformational requirements for the 
interaction of Tyr residues.  DiY modification leads to selective proteolysis, and the released 
DiY is a stable and useful biomarker for oxidative stress, for example as excreted in urine (28). 
 Although not as widely studied as 3NY, these other modifications have been linked to 
atherosclerosis (23), cataracts (24,44), levodopa therapy for PD (18), and lysosomal dysfunction 
(18,19).  Some proteomic studies of DOPA, for example, have been published (39,95), but here 
the focus will be on recent mechanistic studies. 
Age-Related Cataracts 
The formation of age-related cataracts in humans is a sociated with up to 15-fold 
increases in protein-bound DOPA, as well as elevated levels of DiY and other protein-bound 
amino acid hydroxylation products, which can contribute to the protein cross-linking and 
browning that characterize cataractous lenses (24). DOPA and DiY formation may result from 
both Fenton-type, hydroxyl-radical chemistry (24) and reactions photosensitized by protein-
bound Trp metabolites (44).  The free Trp metabolites kynurenine, 3-hydroxykynurenine, 3-
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hydroxykynurenine-O-β-D-glucoside, 4-(2-aminophenyl)-4-oxobutanoic acid, and 4-(2-amino-3-
hydroxyphenyl)-4-oxobutanoic acid serve as filters for UVA light, as they absorb with high 
efficiency but are poor sensitizers for the formation of singlet oxygen or radical species.  
However, with aging, they become increasingly bound to lens proteins, either covalently or non-
covalently (Fig. 4).  Such protein-filter adducts accumulate in the lens nucleus, due at least in 
part to a diffusional barrier that develops at middle age.  In this state, these compounds may lose 
their protective function and instead promote direct and indirect photooxidation of proteins, 
including generation of DOPA and DiY.  At the same time, the pool of free, protective filter 
compounds is depleted, leaving the aging lens more susceptible to photochemical damage (44). 
 
Fig. 4.  Trp metabolites can form covalent or non-covalent associations with proteins to 
become photosensitizers for protein oxidation.  Figure based on information from (44). 
When tested in vitro with soluble bovine lens proteins (44), all but one of these protein-
Trp metabolite adducts led to increased peroxide formation (primarily hydrogen peroxide) in a 
process that is sensitive to D2O (increased yield) and azide (decreased yield), inicating the 
involvement of singlet oxygen.  However, the levels of DOPA and DiY were metabolite-
dependent and insensitive to D2O.  In addition, DOPA formation was independent of 
illumination and atmospheric oxygen.  The authors po tulated at least two reaction pathways to 
account for these differences: 1) the photosensitized formation of singlet oxygen and 2) the 
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autoxidation of the o-aminophenol moiety in 3-hydroxykynurenine or its metabolite, 4-(2-amino-
3-hydroxyphenyl)-4-oxobutanoic acid, which generates superoxide.  Furthermore, in the light-
dependent pathway, the excited states of the filtercompounds appear to have competing energy 
transfer pathways, either to oxygen or to protein-bound Tyr. 
Regardless of the pathway, these phenomena generated covalent, non-disulfide protein 
cross-links and may also contribute to lens browning, two characteristic features of age-related 
nuclear cataracts (24,44).  The DOPA levels in the Trp metabolite study (44) were similar to 
those found in human type IV nigrescent cataract lenses, while DiY levels were much higher in 
the model system than in the cataract lenses.  Cross-links observed by reducing SDS-PAGE may 
be due to DiY and/or reaction of nucleophilic side chains with the protein-bound oxidation 
products of DOPA (i.e. DQ) or the o-aminophenol moiety of 3-hydroxykynurenine or  4-(2-
amino-3-hydroxyphenyl)-4-oxobutanoic acid (.e. o-quinone imine). 
Lysosomal Accumulation 
 Using metabolic incorporation of DOPA into proteins, Dunlop et al. (19) showed that 
such proteins form autofluorescent, SDS-stable, proteolysis-resistant aggregates in J774 murine 
macrophages, similar to the “aging pigment” lipofuscin or its disease-related counterpart, ceroid.  
This aggregation is consistent with the ability of DOPA to oxidize to DQ and react with 
nucleophiles, such as cysteine residues, to form cross-links.  The perinuclear punctate pattern of 
fluorescence and upregulation of the lysosomal proteases cathepsins B and L indicate 
accumulation of these aggregates in lysosomes.  Lysosomes are rich in transition metals due to 
their role in autophagic degradation of metal-containing proteins, and DOPA redox cycling can 
continually regenerate these reactive species to fuel oxidative damage to the lysosomal 
membrane, setting off a lysosomal pathway to apoptosis, as illustrated in Fig. 5 [see (36) for a 
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review].  Indeed, in a subsequent study (18), the authors repeated this result in THP1 human 
monocytes and used a variety of fluorescent staining/flow cytometry approaches to demonstrate  
Fig. 5.  Lysosomal pathway to apoptosis mediated by the accumulation of aggregated proteins 
following metabolic incorporation of DOPA.  Figure based on information from (18,36). 
lysosomal membrane permeabilization, depolarization of mitochondrial membranes, decreased 
mitochondrial cytochrome c levels, and increased apoptosis (measured as phosphatidylserine 
externalization by Annexin V-FITC, cellular DNA conte t by propidium iodide, and DNA 
fragmentation by TUNEL).  Lysosomal membrane permeabiliz tion occurred even in the 
presence of a pan-caspase inhibitor, demonstrating that it is not caused by an early release of 
caspases and thus indicating that it is the trigger for the apoptotic event.  In the absence of the 
inhibitor, Western blots showed the cleavage of pro-caspase 3 to its active form, which is a key 
step that commits cells to apoptosis, and the resulting increase in activity was measured using a 
fluorigenic substrate.  Lysosomal membrane permeabiliz tion was also replicated in SH-SY5Y 
human neuroblastoma cells and MRC5 human lung fibroblasts. 
13 
 
 Similar experiments with o-Tyr, m-Tyr, Tyr, and D-DOPA (a negative control for protein 
incorporation) showed that these effects are unique to protein-bound DOPA (18,19).  While o-
Tyr did induce lower levels of apoptosis than DOPA, as well as lower levels of caspase 3 
activation, it did not aggregate or accumulate, indicating a separate apoptotic pathway (18). 
By specifically incorporating DOPA into cellular proteins in vitro, the study just 
described isolates this protein modification from other possible consequences of oxidative stress 
and defines the subsequent pathway to apoptosis.  It also mimics long-term levodopa treatment 
of PD patients, for whom protein incorporation has been observed (18), and the apoptotic events 
observed may contribute to the suspected neurotoxicity of this treatment regimen.  The 
lysosome-mediated apoptotic pathway may be particularly relevant for neurons and other post-
mitotic cells that are more prone to accumulation of pr teolysis-resistant proteins (18).  Even 
without apoptotic events, the accumulation of non-degradable proteins or lipofuscin in lysosomes 
can lead to mitochondrial dysfunction, a phenomenon observed in long-lived post-mitotic 
senescent cells that may contribute to aging (36). 
It should also be noted that sites of metabolic DOPA incorporation could very well be 
different from those sites altered by ROS in vivo.  Perhaps this study is a better indication of 
events occurring in large-scale oxidative stress events (indeed, aggregation of DOPA-containing 
proteins occurs only when this oxidized amino acid is incorporated in larger amounts (19)), but 
not of localized effects that may result from highly specific redox events, such as the metal-
catalyzed oxidation of Tyr in an enzyme’s active sit .  Complementary proteomic studies could 
identify whether there are common sites for metabolic incorporation versus oxidative damage 
and if any of these sites may be functionally signif cant, especially at lower levels of oxidative 
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insult.  Such proteomic studies and corresponding structural and functional studies for DOPA are 
currently lacking in the field. 
1.1.4 3-Chlorotyrosine 
Formation and Significance 
 The enzyme myeloperoxidase (MPO) is secreted by neutrophils, monocytes, and some 
macrophages and is a key component of inflammatory response (94).  It uses hydrogen peroxide 
and chloride ions to generate hypochlorous acid (HOCl) as a defense against microorganisms, 
but it can also inflict oxidative damage on proteins and lipids (59).  HOCl can react with protein-
bound Tyr, and this is the only known source of 3ClY formation in humans, making this 
modification a good fingerprint for oxidative damage promoted by MPO (30,59).  HOCl can 
further chlorinate 3ClY to form DiClY (81).  In addition, MPO can generate •NO2 from nitrite or 
ONOO−, which can generate 3NY, as well as tyrosyl radicals, leading to DiY and other Tyr-
derived cross-links (52,59).   
3ClY has been found in many inflammatory disease state , such as in synovial fluid from 
rheumatoid arthritis patients (89).  In addition, both MPO and its products, particularly 3ClY and 
3NY, are known to be enriched in human atherosclerotic plaques and in plasma from patients 
with cardiovascular disease (9,30,94).  Indeed, plasma MPO level has been shown to be an 
effective predictor of major adverse coronary events i  patients presenting with chest pain to the 
emergency department (9). 
Chlorination of HDL May Contribute to Atherogenesis 
Studies of specific 3ClY sites in proteins are scarce, but there has been interest in 
characterizing the role of MPO in the oxidative damage of high-density lipoprotein (HDL), 
particularly its major protein component, apolipoprtein A-I (apoAI).  Fig. 6 shows the locations 
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of several important oxidation sites.  While there is 
agreement in the literature that MPO selectively 
targets Tyr-192 (a highly conserved residue) in 
lipid-free apoAI for both chlorination and nitration, 
with lower levels observed at the other six Tyr 
residues (69,97), the functional impact of this 
specific modification is controversial.  There is 
agreement that MPO-mediated modification, and 
specifically the 3ClY and 3NY content of apoAI, 
correlates with loss of cholesterol efflux activity 
mediated by ATP-binding cassette transporter A1 
(ABCA1) (69,96) and that both chlorinated and 
nitrated apoAI are enriched in human plasma from 
patients with cardiovascular disease and even more 
so in atheromas isolated from such patients (96,97).  
Shao et al. (69) further demonstrated that the 
specific modification of Tyr-192 to 3ClY shows a 
strong linear correlation with the loss of ABCA1-
dependent cholesterol efflux activity.  Additional, contradictory findings are briefly described 
below, and for recent related reviews from both groups actively researching this subject, see 
(70,77).  
In a series of studies, the groups of Heinecke and Oram described roles for Tyr, Lys, and 
Met residues in the MPO-mediated inactivation of apoAI cholesterol efflux activity via ABCA1.  
Fig. 6.  Oxidation sites of lipid-free 
human apoAI, many of which are 
located near hinge regions that may be 
important for rearrangement upon lipid 
association and subsequent binding to 
ABCA1 for reverse cholesterol 
transport activity.  Lys-195 facilitates 
chlorination of Tyr-192.  Image derived 
from the crystal structure stored in the 
Protein Data Bank (3); accession code 
2A01.  Figure generated using Protein 
Workshop (45). 
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While Tyr-192 was the major target for both chlorinat on and nitration by MPO (and also 
nitration by ONOO−), the latter modification did not significantly affect the biological activity 
(69).  Nearby Lys residues on the same face of the amphipathic helix as Tyr, specifically in 
YXXK motifs, regiospecifically directed Tyr chlorination via chloramine intermediates formed 
on the ε-amino group of Lys (6,71).  Point mutations designed to add or remove Met residues 
near target Tyr residues showed their capacity to act as intramolecular antioxidants to inhibit the 
chlorination (71), as also demonstrated in a later study by Peng et al. (55). 
Paradoxically, Shao et al. (71) presented evidence that Met oxidation, along with Tyr-192 
chlorination, was required to impair cholesterol transport activity of apoAI.  Mutation of Tyr-192 
to the more MPO-oxidation-resistant Phe (Y192F) gave  functional apoAI that was protected 
slightly from chlorination-dependent loss of activity.  Following quantitative oxidation of all 
three native Met residues to Met sulfoxide by the MPO system, their complete conversion back 
to Met by the methionine sulfoxide reductase enzyme PilB resulted in partial recovery of 
activity.  While neither of these strategies led to full recovery on its own, the combination of the 
Y192F mutation and PilB treatment almost completely r stored the activity to that of 
unmodified, wild-type apoAI, leading to the conclusion that both Tyr-192 chlorination and Met 
oxidation contribute to MPO-mediated functional impairment. 
Toward an understanding of the mechanism underlying impaired reverse cholesterol 
transport, Shao et al. (72) showed that while both unmodified and nitrated apoAI were able to 
compete with 125I-labeled apoAI for binding to ABCA1, the MPO-treatd protein could not.  
Furthermore, their data indicated that the lipid-binding ability of the protein was not 
compromised by MPO treatment.  Since Tyr-192 and all three oxidized Met are in or near hinge 
regions of apoAI (Fig. 6), their modification may interfere with the rearrangement of its hairpin 
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loops that is required for interaction with ABCA1.  The resulting impairment of cholesterol 
removal from lipid-laden macrophages or foam cells would promote formation of atherosclerotic 
plaque (70). 
Other researchers have also independently identified Tyr-192 in apoAI as a major target 
for chlorination by MPO, but their data has not supported a significant functional impact for this 
particular modification in murine macrophages.  Rather, their mutation of all seven Tyr residues 
to Phe conferred no protective effect for cholesterol fflux activity following MPO treatment of 
apoAI (56).  On the other hand, mutation of all four Trp residues to Phe did make apoAI resistant 
to MPO-mediated oxidation, leading to the conclusion that mono- and di-hydroxylated Trp is 
responsible for loss of apoAI’s ABCA1-dependent cholesterol efflux activity (55). 
Acknowledging these discrepancies, Shao et al. (71) suggest that different cell culture 
models may behave differently, specifically proposing that since their ABCA1-transfected baby 
hamster kidney cells express higher levels of ABCA1 than murine macrophages, the modest 
protective effect of replacing Tyr-192 with Phe is more easily detected.  Furthermore, Shao and 
Heinecke (70) point to structural changes in the Trp-free mutant that may explain its resistance to 
MPO-mediated inactivation, rather than the absence of oxidizable Trp.  They specifically cite the 
increase in α-helical content from 56% for the wild-type to 71% in the Trp-free mutant (55,70). 
There are likely many factors that contribute to HDL dysfunction in atherosclerosis [see 
(77) for a useful discussion], of which modification f Tyr and other amino acids is only one.  
Even so, specific characterization of the residues involved in oxidation-mediated protein damage 
may open new diagnostic and therapeutic avenues, both through the use of modified residues as 
biomarkers and the development of oxidation-resistant forms of apoAI as more effective anti-
atherogenic agents for possible therapeutic use (70,71,76).  In particular, the specificity of 3ClY 
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as a marker for MPO activity and the link between MPO and disease progression may make it an 
important diagnostic and/or therapeutic tool. 
1.1.5 Conclusions 
 Tyr modification has been demonstrated to have important consequences for protein 
function and structure in many cases.  In others, there is still an opportunity to learn what impact 
these PTMs may have on particular proteins and whatrole they may play.  As the work of 
identifying, isolating, and characterizing modified proteins under conditions relevant to 
biological aging and age-related diseases continues, novel insights and deeper understanding of 
physiological and pathological processes can ultimately lead to improved diagnostic methods 
and therapeutic  
1.2 Proteomic Approaches to Analyze Protein Tyrosine Nitration 
 This section has previously been published as a review article (21). 
1.2.1 Introduction 
Nitrative Stress Leads to 3-Nitrotyrosine Formation 
 Under conditions of nitrative stress, particularly when nitric oxide combines with 
superoxide to form peroxynitrite, protein Tyr residues can undergo nitration to 3-nitrotyrosine 
(3NY), and increases in 3NY have been correlated to aging and numerous disease states, 
including cardiovascular disease, neurodegeneration, and autoimmune diseases (52).  Tyr 
nitration can alter protein structure and function and may play a role in redox signaling (2,22,62). 
 In order to understand the biological impact of Tyr nitration, protein targets must be 
identified, most often by mass spectrometry (MS)–based proteomics.  Because many reviews of 
nitroproteomic methods exist (2,15,17,34,50,87,92), including several dedicated to MS 
techniques (7,58,67,68), the present review will focus on recent improvements in the field. 
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Some Considerations for the Development of Nitroproteomic Methods 
The field of nitroproteomics has long been dominated by two-dimensional 
polyacrylamide gel electrophoresis (2D-PAGE), followed by Western blotting with antibodies 
against 3NY and analysis of in-gel-digested spots by MS.  This remains the most sensitive 
technique available, routinely indicating endogenous nitration.  However, it is laborious and 
suffers from problems with specificity, background signals, and reproducibility, due in part to 
variations among antibody batches and suppliers (2,34,90).  Antibodies may be either too 
specific, depending on the antigen used to raise them, or not specific enough, as cross-reactivity 
can occur, for instance, with the Trp derivative 5-hydroxy-6-nitrotryptophan (51).  Methods for 
enrichment by immunoprecipitation can suffer from some of the same limitations.  Furthermore, 
2D-PAGE can be biased against proteins on the extremes of size, isoelectric point, and 
hydrophobicity.  Finally, unambiguous identification f nitrated proteins and residues is difficult 
because a single gel spot may contain multiple proteins, and tandem mass spectrometry 
(MS/MS) data are often not obtained for the tryptic eptides containing 3NY (2,34). 
Multi-dimensional chromatography, either on-line or off-line, can partially automate the 
pre-fractionation process for 3NY proteomics.  However, specifically offline pre-fractionation 
can be time-consuming and generate large amounts of samples for MS analysis, thus requiring 
significant instrument time.  Due to the large dynamic range required for proteomic analysis, as 
well as concerns about column capacity and ion suppression of low-abundance species by an 
overwhelming matrix of high-abundance species, detection of low endogenous levels of 3NY [on 
the order of one to five residues per 10,000 Tyr residues in samples under inflammatory 
conditions (62)] depends upon sufficient simplificat on and/or purification of the sample. 
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To address these limitations, many methods for chemical derivatization of 3NY have 
been developed, mostly to enrich 3NY-containing proteins and/or peptides.  These methods often 
involve several derivatization steps, almost always including the reduction of 3NY to 3-
aminotyrosine (3AY) by sodium dithionite (SDT) (78), followed by reaction of the aromatic 
amine with a labeling reagent, along with one or moe cleaning steps.  Derivatization methods 
also present opportunities for relative and absolute q antitation using isotopic labeling and/or 
fluorogenic tagging.  Some derivatization strategies have focused on simplification and 
avoidance of sample losses that inevitably accompany derivatization and cleaning.   
The reduction of 3NY to 3AY can be a challenging step.  The most popular method uses 
SDT (78),  but concomitant 3AY and Tyr sulfation can interfere with MS analysis  (25,26).  An 
alternative method using thiols and heme yields 3AY as a single product but is more sensitive to 
conditions and difficult to automate (4,25,26).  Anelectrochemical 3NY reduction has not yet 
been widely applied in the field of nitroproteomics (2).  3AY may also form inadvertently during 
sample processing, as observed for the Arabidopsis thaliana proteome (41), and may even form 
in vivo (2).  These phenomena should be accounted for in proteomic database searches. 
Labeling the 3AY aromatic amine with high specificity is crucial, due to the very large 
excess of aliphatic amine groups (N-termini and Lys ε-amino groups) over low-abundance, 
endogenous 3NY sites in biological samples, approximated to be ca. 28,000-fold molar excess 
(1).  Some groups have attempted to exploit the lower pKa of the aromatic amine, which is 4.75 
in the free amino acid (78), relative to aliphatic amines (pKa ca. 8-10) to impart specificity in 
labeling.  However, others observed that such pH-based selectivity is insufficient (1,26,93), and 
most methods have added steps to block reactive amines prior to the reduction of 3NY. 
Some Considerations for Mass Spectrometry of Nitrated Peptides and Proteins 
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When matrix-assisted laser desorption ionization (MALDI) is used for ionization, 3NY 
photodegradation can occur with a loss of one or tw oxygen atoms or reduction of 3NY to 3AY 
(10,38,40,58,66).  While some studies use this characte istic pattern to aid in 3NY identification, 
it raises limits of detection because the MS signal i tensity is shared among three or four peaks.  
Electrospray ionization (ESI) avoids this problem but does have some disadvantages, such as a 
lower tolerance for sample contaminants and matrix components.  Regardless of the ionization 
source, both 3NY- and 3AY-containing peptides can hve low ionization efficiency and/or poor 
MS/MS fragmentation (1,26,35,38,58,85).  3AY may give deviating isotopic envelopes for 
fragment ions, possibly due to chemical rearrangements, which can interfere with protein 
database searching and prevent proper identification (26).  Derivatization of 3AY can overcome 
these problems (26,60).  Removal of the nitro group, an “electron predator,” enables the use of 
electron capture and electron transfer dissociation as complementary fragmentation methods to 
improve sequence coverage (60); see Refs. (31,43) for further discussion. 
1.2.2 Multidimensional Chromatography 
 Technical and methodological advances have benefitd nitroproteomic studies (2,7,8,79). 
More recent developments are discussed below. 
COFRADIC 
Ghesquière et al. (25) applied combined fractional diagonal chromatography 
(COFRADIC) to nitroproteomics.  Protein digests areseparated by reverse-phase (RP) high-
performance liquid chromatography (HPLC) and fractions collected over one-minute intervals.  
After reduction of 3NY to 3AY with SDT, samples are again fractionated using the same RP-
HPLC conditions, and peaks showing a hydrophilic shft are collected for MS identification.  
While this method requires tedious fraction collection, it successfully identified six in-vivo 
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nitration sites in four different proteins from serum in a mouse model of sepsis, specifically 
female C57BL6/J mice injected intravenously with pathogenic Salmonella enteritidis.  Likewise, 
3NY sites were identified from in-vitro nitration models, such as bovine serum albumin (BSA) 
treated with tetranitromethane (TNM) and Jurkat cell lysate exposed to peroxynitrite. 
The authors also observed sulfated 3AY as a side product of reduction of Jurkat cell 
samples by SDT, where ca. 84% of peptides were partially sulfated.  Thus, it is mportant to 
include sulfation when searching MS data against proteomic databases in experiments that use 
SDT. 
 Larsen et al. (37) combined COFRADIC with off-line nano-HPLC-MALDI-MS with 
tandem time-of-flight detection in a study that was limited to BSA nitrated in vitro, for which 
this method identified five 3NY sites.  Advantages include the small amount of sample required 
and the potential for automation. 
1.2.3 Fluorescent Labels 
 Incorporation of fluorescent moieties into nitropeptides or nitroproteins can provide a 
powerful tool for detection, with high signal-to-noise ratios, as well as for absolute and/or 
relative quantitation and for visualization in gels, Western blots, or tissue samples.  
6-Substituted 2-Phenylbenzoxazoles 
 Several studies have demonstrated fluorogenic labeling of 3NY by reduction to 3AY with 
SDT followed by reaction with benzylamine (57,74) or benzylamine derivatives, 4-
(aminomethyl)benzenesulfonic acid (ABS) (73) or (3R,4S)-1-(4-
(aminomethyl)phenylsulfonyl)pyrrolidine-3,4-diol (APPD) (16) (Fig. 7).  A major advantage of 
this strategy is the selectivity for the o-aminophenol moiety of 3AY, which precludes the need to 
block other reactive amines in the peptide or protein.  The products are highly fluorescent 6-
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substituted 2-phenylbenzoxazoles.  For each reagent, three products have been characterized that 
differ in the substituent at the 6-position of the benzoxazole ring system but maintain similar 
fluorescent properties.  Labeling can be followed by fluorescence detection and identification by 
MS.  The method has also been applied for histochemical staining (75). 
24 
 
 
  
Fig. 7.  Fluorogenic derivatization of 
3NY to 6-substituted 2-
phenylbenzoxazoles.  Adapted and 
modified from Refs. (16,73,74).  RT = 
room temperature, FL = fluorescence 
detection, UV = ultraviolet absorbance 
detection, TOF = time-of-flight, capLC 
= capillary liquid chromatography, LTQ 
= linear trap quadrupole (linear ion 
trap), FTICR = Fourier transform ion 
cyclotron resonance. 
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For a synthetic nitropeptide, FSA(3NY)LER, tagged with ABS, the fluorescence 
quantum yield was determined as 0.77 ± 0.08 (73), and limits of detection by fluorescence 
spectrometry were measured as 12pmol and 40pmol for the nitropeptide alone and in the 
presence of 100µg digested proteins from C2C12 murine myoblasts, a model background matrix, 
respectively.  Each of the reagents is amenable to iso pic coding for MS-based relative 
quantitation (57,74). 
Notably, 3,4-dihydroxyphenylalanine and 5-hydroxytryp ophan can also be labeled by 
this method, without reduction by SDT (73).  The idntity of the detected post-translational 
modification (PTM) can thus be deduced using controls n t treated with SDT. 
1.2.4 Affinity Labels 
In order to avoid ion suppression of low-abundance itropeptides, as well as to address 
chromatographic capacity limits, specific and efficient labeling of 3NY for affinity-based 
enrichment is a promising strategy for nitroproteomics.  There has been great interest in 
developing antibody-free methods to overcome disadvantages of specificity, reproducibility, and 
throughput. 
Boronate Affinity 
 In the most recent development of a fluorogenic labeling strategy (57,73,74), Dremina et 
al. (16) describe a new benzylamine-derived reagent for derivatization and affinity enrichment of 
3NY using boronate-affinity HPLC (BA-HPLC) (Fig. 7).  The reagent APPD contains a 
benzylamine moiety for reaction with 3AY and a cis-diol moiety for pH-dependent coordination 
with boronic acid. 
 Both fluorescence spectrometry and BA-HPLC data (with fluorescence detection) can be 
used for quantitation of 3NY by this method, with limits of detection calculated as 19nmol and 
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13pmol, respectively, for a digest of rabbit phosphorylase b nitrated in vitro by peroxynitrite, 
alone or in a matrix of digested C2C12 murine myoblast proteins.  Side product(s) can increase 
background and detection limits, but enrichment by BA-HPLC attenuates this problem. 
Biotin 
The high-affinity interaction of biotin with avidin and streptavidin makes it an attractive 
labeling moiety.  As reviewed elsewhere (2,50), several groups have developed methods for 
biotinylation followed by enrichment on immobilized avidin or streptavidin. 
 The method of Abello et al. (1), summarized in Fig. 8, reduces the need for cleaning steps 
and pH changes, thus minimizing sample losses.  Aliphat c amines are acetylated by N-
hydroxysuccinimide (NHS) ester, 3NY is reduced to 3AY using the dithiothreitol/hemin system, 
and a large excess of biotinyl NHS ester completes th  derivatization.  Following both NHS-
based reactions, heating in a bath of boiling water degrades remaining reagent and reverses any 
Fig. 8.  Method for biotinylation of 3NY for affinity-based enrichment.  This particular 
method minimizes sample cleaning steps.  Adapted and modified from Ref. (1).  NHS-acetate 
= acetic acid NHS ester, DMSO = dimethyl sulfoxide, DTT = dithiothreitol, NHS-biotin = 
biotinyl NHS ester, SCX = strong cation exchange, GnHCl = guanidinium hydrochloride. 
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undesirable O-acetylation or O-biotinylation.  The single cleaning step required, a strong cation 
exchange solid-phase extraction (SPE) used to remov remaining biotin reagent, has poor 
recovery.  After cleaning, the biotinylated peptides are enriched using a monomeric avidin resin 
and elution by guanidinium hydrochloride under acidic conditions.  
The peptide angiotensin II (Ang II) was nitrated in vitro by peroxynitrite and spiked into 
a tryptic digest of BSA as a model system.  Although the peptide was successfully labeled and 
recovered, the SPE cleaning step is a major source of sample loss.  Therefore, the authors 
propose future work to perform all derivatization reactions on intact proteins, such that size-
based separation methods (e.g., gel filtration or dialysis) can be used instead.   
Metal Chelation 
 A new adaption of immobilized metal affinity chromatography (IMAC) has been 
developed by Lee t al. (38) for the enrichment of 3NY-containing peptides (Fig. 9).  Primary 
amines are blocked by acetylation with sulfo-NHS-acet te prior to SDT reduction of 3NY to 
3AY, after which the latter undergoes Schiff base formation and reductive amination with a large 
excess of pyridine-2-carboxaldehyde and sodium cyanoborohydride to give peptides that are 
bispyridinylated at the original nitration sites, with small amounts of monopyridinylation.  
Desalting steps are required following each of these r actions.  The labeled peptides now chelate 
nickel (II) attached to magnetic agarose beads.  After binding and washing, peptides are released 
with imidazole or ethylenediaminetetraacetic acid, desalted, and identified by MALDI-MS with 
time-of-flight detection. 
 This approach was applied to synthetic nitrated Ang II and to BSA nitrated by TNM.  
The authors demonstrate detection of as little as 100fmol of nitropeptide spiked into a matrix of 
10µg HeLa cell lysate.  As absolute signal intensity values are not presented with the MS data, it 
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is unclear whether significant peptide losses occur during derivatization and cleaning steps.  
Also, while the mass shifts are generally in accord with expected values for each reaction step, 
all of the observed m/z values for Ang II and its derivatives appear higher t an the corresponding 
theoretical values, with mass errors of 580-1080ppm, a phenomenon also seen in the data of Kim 
et al. (35) (described below).  
Fluorine Affinity 
 Some of the same researchers have also developed a strategy to derivatize 3NY with 
highly fluorinated moieties for enrichment by fluorinated SPE (FSPE) (35) (Fig. 10).  After 
acetylation of aliphatic amines with sulfo-NHS-acetat  and reduction of 3NY to 3AY with SDT, 
peptides are tagged with N-succinimidyl 3-(perfluorobutyl)propionate, with cleaning steps after 
each reaction.  Labeled peptides are enriched using FSPE, and the eluates are analyzed by MS. 
Fig. 9.  IMAC method for enrichment of 3NY-containing peptides, by bispyridinylation of 
3NY.  Adapted and modified from Ref. (38).  NTA = nitrilotriacetic acid, EDTA = 
ethylenediaminetetraacetic acid. 
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Using this strategy for synthetic nitrated Ang II mixed with its non-nitrated counterpart, 
successful derivatization and enrichment are demonstrated by MALDI-MS.  Interestingly, the 
absolute MS intensity for the tagged peptide is much greater after FSPE than before, and, while 
not discussed in the article, this may be an indication of ion suppression in the crude sample that 
is overcome by the affinity purification step. 
However, as in the IMAC study (38), there are systematic deviations of observed m/z 
values from the theoretical values, especially for nitrated Ang II and its derivatives, which show 
large mass errors of +580-1038ppm.  The mass shifts after each reaction are generally as 
expected, except for ∆m/z=46.1 between native and nitrated Ang II (the expected value is 45.0).  
Fig. 10.  Method for fluorination of 3NY for purification by FSPE.  Adapted and modified 
from Ref. (35).  ACN = acetonitrile, THF = tetrahydrofuran, TOF/TOF = tandem time-of-
flight, IT = ion trap. 
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Inadequate instrument calibration is one possible explanation for this combination of 
phenomena, but the article does not discuss it.  Also, there are some additional peaks in the final 
product spectrum that are not explained.  Among them is a small peak near 1100 m/z, which 
could represent amino-Ang II (1104 m/z), but the absence of annotation for this peak preclud s a 
definitive determination.  At the characteristically low ionization efficiency of the amino-
peptide, even a small peak can represent a significa t amount of peptide that was not tagged. 
The decrease in absolute intensity of the MALDI peak for the non-nitrated, acetylated 
peptide following subsequent steps probably results from sample losses due to cleaning, or 
perhaps due to reaction conditions (e.g., possible side products or peptide degradation).  These 
losses can become very important when looking for low-abundant PTMs, like 3NY. 
The method was able to tag, enrich, and detect 100pmol of nitrated Ang II in a 
background of 10µg of a BSA tryptic digest.  More notably, 28 endogenously nitrated peptides 
from 28 proteins were identified in the Huh7 human hepatoma cell line, and the 3NY sites were 
confirmed by MS/MS with manual validation.  Some of the peptide spectra show XCorr scores 
[cross-correlation values generated by the SEQUEST algorithm (20)] that are lower than ideal, 
possibly indicating a poor fit to the theoretical spectra for the assigned peptide sequences.  The 
most intense peaks in the MS/MS spectra are assigned, but only one spectrum shown has 
backbone cleavages on both sides of the tagged Tyr, which is stronger evidence for nitration site 
assignment.  Not all of the Lys residues are acetylated, even though the text listed this 
modification as a requirement for acceptance of the identification.  In contrast, all of the N-
termini are acetylated in the identified peptides.  For two of the identifications, the nitration site 
is located in a specific functional domain. 
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1.2.5 Solid-Phase Chemistry 
Several methods have used covalent reactions between th  peptide of interest and a solid-
phase reagent, followed by chemical cleavage to recver the peptide with a vestigial tagging 
moiety that can be identified during MS analysis.  Recent studies have endeavored to improve 
upon the earlier methods of Zhang et al. (93) and Nikov et al. (49). 
Chemoprecipitation Using Solid-Phase Activated Ester R agent 
 In order to simplify the derivatization procedure and avoid sample losses incurred by 
cleaning steps, Prokai-Tatrai et al. (60) developed a chemoprecipitation technique in which 
amine groups are blocked by reductive methylation, 3NY is reduced to 3AY, and the latter reacts 
with a solid-phase active ester reagent (SPAER) on glass beads, followed by washing and gentle 
acid-catalyzed hydrolysis to remove the peptides, which retain a 4-formylbenzoylamido group 
(Fig. 11).  By solution methods, the dimethylation step requires clean-up by SPE, but a one-pot 
method using solid-phase reagents is also reported.  Importantly, dimethylation prevents non-
selective labeling of amine groups while retaining their ability to ionize for facile detection in 
positive-mode HPLC-ESI-MS/MS. 
 In addition to identifying tagged derivatives of three synthetic nitropeptides in a BSA 
tryptic digest matrix (>200-fold molar excess of unmodified over nitrated peptides), 32 unique 
tagged peptides were identified from 12 different proteins in a tryptic digest of human plasma 
samples that were nitrated in vitro by TNM, some of which were previously found nitrated in 
aging and disease states.  Eight contaminating, unmodified peptides from plasma proteins were 
also identified.  This is attributed to non-specific adsorption to the beads, which the authors 
propose to address by more thorough washing with organic solvents. 
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 Building upon this work, Guo et al. (29) developed a method for relative quantitation by 
using isotopically labeled formaldehyde for reductive methylation, which did not alter the 
chromatographic properties of the products.  This method was successfully applied to two model 
systems: synthetic nitropeptides spiked into a matrix containing the tryptic digest of human 
serum albumin and the model protein ubiquitin nitrated in vitro and spiked into a matrix of 
human plasma (29). 
1.2.6 Quantitation 
 An important strategy for quantitation of 3NY consist  of using isotopically coded 
reagents for differential labeling of samples from two (or more) experimental conditions and 
mixing these samples prior to MS analysis, thus allowing for quantitative comparisons of ion 
Fig. 11.  SPAER method for enrichment of 3NY by chemoprecipitation.  This represents 
the solution-phase method, but a solid-phase method was also tested.  Adapted and modified 
from Ref. (60).  Incorporation of isotopic labels for relative quantitation is further described 
in Ref. (29).  TFA = trifluoroacetic acid.  
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peak areas.  While this is largely applied to relative quantitation, there are ways to achieve 
absolute quantitation by including an isotopically labeled internal standard.  Isobaric tagging 
strategies have also emerged, which maintain a single m/z value for precursor ions but yield 
specific reporter ions after fragmentation, with the latter used for quantitation.  These include 
tandem mass tags (TMT) (83) and isobaric tags for relative and absolute quantitation (iTRAQ) 
(64). 
iTRAQ 
The iTRAQ method was developed based on labeling primary amines for profiling whole 
proteomes (64).  By acetylating primary amines with acetic acid NHS ester, then reducing 3NY 
to 3AY with SDT, and finally labeling 3AY with iTRAQ reagents, with some cleaning 
procedures required, Chiappetta et al. (10) have adapted the iTRAQ methodology for 
identification and quantitation of 3NY sites (Fig. 12).  Nano-HPLC-ESI-MS/MS was performed 
in the precursor ion scanning mode for specific repo ter ions, which enabled the use of the mass 
spectrometer’s duty cycle for analyzing only peptides of interest and thus enhanced the limit of 
detection without the need for affinity purification/enrichment.  
Fig. 12.  Relative quantitation of 3NY with an adaptation of the iTRAQ method.  
Adapted and modified from Ref. (10).  TEAB = tetraethylammonium bicarbonate. 
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This method was applied to BSA nitrated in vitro by TNM, alone or in the presence of 
30mg of E. coli protein extract, and to bovine milk proteins nitrated in vitro with TNM.  For the 
latter, nine 3NY sites were identified, which were found in both high- and low-abundance 
proteins, with accurate relative quantitation for seven of them. 
Two-Dimensional Isotopic Coding 
 Building on previous work (84), Tsumoto et al. (85) developed a method to increase the 
ionization efficiency of tryptic nitropeptides, prevent their photodecomposition during MALDI 
experiments, and incorporate isotopic labels (Fig. 13)  Due to the two-dimensional nature of this 
isotopic labeling strategy, with the first dimension applied to all peptides and the second 
dimension applied only to 3NY, both non-nitrated an nitrated peptides are quantitatively 
compared between two samples in a single experiment.  This feature was used to quantify the 
degree of nitration achieved by in-vitro methods for specific Tyr residues.  Although not 
explicitly discussed, it could also be very useful to control for protein expression levels, an 
important concern for comparative proteomic profiling of PTMs.  Any 3NY labeling strategy 
that includes a step to block aliphatic amines could likely be adapted to take advantage of this 
feature. 
 Following acetylation of aliphatic amines with light or heavy acetic anhydride, 3NY is 
reduced to 3AY by SDT for subsequent tagging with 1-(6-
methyl[D0/D3]nicotinoyloxy)succinimide, with appropriate cleaning procedures, followed by MS 
analysis.  
 Two model systems were used, synthetic nitrated Ang II and BSA nitrated in vitro with 
peroxynitrite.  Ionization efficiency of tagged peptides was greatly improved compared to their 
3NY- or 3AY-containing counterparts, recovering to about the same level as the acetylated, non-
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nitrated peptide.  Since no absolute intensities ar shown for the mass spectra, it is not possible to 
compare samples for peptide losses during derivatization and cleaning steps.  
cPILOT 
Robinson et al. (63) developed the method of combined precursor isotopic labeling and 
isobaric tagging (cPILOT) in order to multiplex as many as 16 samples, using the previously 
reported isobaric tagging methods TMT (83) and iTRAQ (64) (Fig. 14).  This allows for 
simultaneous comparison of numerous biological samples, which is more cost-efficient.  After 
acetylating amines with light or heavy N-acetoxysuccinimide to give duplexed samples, SDT 
reduces 3NY to 3AY, and sets of either TMT or iTRAQ reagents complete the derivatization, 
with up to 16-plex experiments possible in theory and no cleaning steps required until 
immediately prior to MS. 
Fig. 13.  Method for isotopic coding of 3NY for quantitation.  Adapted and modified from 
Ref. (85).  Ac2O = acetic anhydride. 
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Using BSA nitrated in vitro by peroxynitrite as a model, a 12-plex experiment (duplexed 
acetylation combined with 6-plex TMT) showed overlap in the precursor ion isolation, causing 
inaccurate quantitation (63).  For investigation of unknown, in-vivo nitration sites in the mouse 
spleen proteome, scaling back to 4-plex still result d in some overlap, but the relative 
quantitation was accurate nevertheless.  Notably, five endogenous nitration sites were identified 
from five unique proteins.  Possible improvements iclude enrichment strategies prior to labeling 
to increase proteomic identifications and an increase in the mass shift for the first dimension of 
isotopic labeling to overcome the problem of precursor ion overlap. 
Fig. 14.  Multiplexed method for relative quantitation of 3NY in up to 16 samples.  
Adapted and modified from (63). 
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1.2.7 Conclusions 
 Despite many successful proof-of-concept studies with model systems, detection of 
endogenous 3NY remains a significant challenge.  At present, most endogenous 3NY 
assignments are still based on 2D-PAGE/Western blot and immunoprecipitation methods (2).  Of 
the recent studies covered in this review, only three (25,35,63) successfully identified in-vivo 
nitration sites, for a total of 39 sites in 37 different proteins.  Other successful studies (65,95) did 
not derivatize 3NY but used pre-fractionation and advanced HPLC-MS equipment, most notably 
capillary columns that were 65cm in length, compared to 10-15cm for most other studies. 
This difficulty may be due to a combination of very low levels of endogenous 3NY and 
sample losses during derivatization and cleaning steps.  Many studies (1,10,16,29,35,38,85) rely 
on the disappearance of mass spectral peaks for the starting materials to demonstrate “complete” 
conversion for each reaction.  However, this is not a truly quantitative technique, especially 
when MALDI is used, and furthermore this data cannot account for sample losses (e.g., due to 
adsorption on plastic or glassware) or undetected side products. 
Successful nitroproteomics requires selective separation and/or purification of 
nitropeptides from the matrix of non-modified peptides in order to reduce ion suppression and 
remain within limits of column capacity for HPLC-MS/MS.  This must be done with a minimum 
of sample losses, especially considering the low abundance of 3NY in vivo and the small 
amounts of biological material that are often available from precious specimens.  Indeed, several 
of the most successful methods to date have either avoided 3NY derivatization completely 
(65,95) or kept it to a minimum (25). 
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1.3 Specific Aims 
  Toward the goals of labeling, enrichment, identification, and relative quantitation of the 
protein oxidation products 3,4-dihydroxyphenylalanine (DOPA) and 3-nitrotyrosine (3NY), this 
thesis project applies benzylamine-dependent chemistry to model peptides, model proteins, and 
cardiac tissue samples from a rat model for aging.  This project encompasses method 
optimization, the effect of primary structure on tagging properties, and the search for potential 
age-dependent differences in cardiac protein modificat on.  Based on previous evidence of 3NY 
accumulation in cardiac proteins during aging (32), as well as other conditions of oxidative stress 
like diabetes (86), this tissue was selected for application of the novel labeling method.  Many 
challenges of translating such a method from simple model systems to complex biological 
sample are explored, and a variety of optimization efforts are described.  In addition, the model 
protein glycogen phosphorylase b (Ph-b) is used to measure the method’s limit of detection by 
fluorescence spectrometry and to study the effect of the cardiac homogenate matrix on 3NY 
residues.  Finally, a series of model peptides are lab led and quantitatively analyzed to determine 
fluorescence quantum yields, molar absorptivities, and chemical reaction yields of labeled 
products and to compare these properties in peptides of varying sequence and physicochemical 
properties. 
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Chapter 2:  Searching for Endogenous 3-Nitrotyrosine (3NY) and 3,4-
Dihydroxyphenylalanine (DOPA) Modifications in Aging Rat Cardiac Tissue 
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2.1 Introduction 
2.1.1 Significance of and Evidence for Protein Oxidation in Aging Rat Cardiac Tissue 
 As discussed extensively in Chapter 1, oxidative post-translational modifications (PTMs) 
of proteins can significantly alter protein structure and function and thus lead to dysfunction in 
cells and tissues.  Of particular interest is the accumulation of modifications on specific Tyr 
residues within specific proteins during biological aging, as well as age-related diseases (3).  By 
identifying proteins affected by such modifications, pathological mechanisms can be uncovered 
and used to inform development of therapeutic, diagnostic, and/or preventative measures. 
 Previous studies have shown age-dependent increases in Tyr-nitrated proteins in cardiac 
tissue from rats (4).  Both 3NY and DOPA have been id tified in a proteomic study of mouse 
brain and heart tissue (12).  Notably, both studies id ntified endogenous modifications, which is 
substantially more difficult – and more biologically relevant – than identifying modification sites 
following treatment with nitrating or oxidizing agents in vitro. 
2.1.2 Proteomics: Promise and Challenges 
 Before studying the effect of specific Tyr modifications on the function of particular 
proteins that may be involved in pathological processes, it is first necessary to discover where 
these modifications occur to an extent large enough to effect meaningful changes in biological 
processes.  This challenge is part of the field of pr teomics. 
 Section 1.2 describes in detail the most current stra egies in proteomic studies of 3NY, 
most of which involve derivatization of this modified residue to aid in its enrichment, detection, 
and quantitation (2).  DOPA is a much less-studied mo ification, and there is a scarcity of 
proteomic studies focused on it.  A major challenge i  this field is the low abundance of 
modified residues within the bulk proteome of a sample.  However, this low abundance does not 
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preclude the capacity for significant biological effects.  Since modifications can accumulate on 
specific proteins and at specific sites within those proteins, a 3NY or DOPA concentration that is 
dwarfed by the total protein concentration of a bulk sample can still exist on a high percentage of 
copies of a specific protein and thus significantly affect protein activity.  This is especially true 
for proteins that have large biological effects even at low concentrations, such as signaling 
proteins. 
The complexity of “real,” biological samples presents many challenges when adapting a 
method that has been developed with model systems of relatively pure peptides, proteins, and 
small molecules.  These include interfering species in the biological matrix, unknown (and 
typically very low) amounts of the analyte of interest (here, 3NY and DOPA), and the effects of 
a variety of sample preparation conditions on protein integrity and recovery.  Furthermore, while 
the goal of proteomics is to identify as wide a range of protein targets as possible, the 
physicochemical and structural properties of these targets vary widely and can affect the results 
of labeling reactions and of behavior in mass spectrometry studies.  Thus, it is nearly impossible 
to find one set of “optimal” conditions for all of the proteins in a sample. 
2.1.3 Novel Fluorogenic Derivatization Chemistry with Benzylamine 
 This project aims to contribute to the field of 3NY and DOPA proteomics by employing a 
novel strategy for labeling these oxidative PTMs with fluorogenic and affinity moieties to enable 
their detection, identification, and ultimately quantitation.  Sections 1.2.3 and 1.2.4 describe this 
method, which relies on benzylamine (BA)-based chemistry to convert 3-aminotyrosine (3AY) 
to a fluorescent 2-phenylbenzoxazole.  In addition o the parent benzylamine reagent, which is 
commercially available, derivatives have been prepar d to either enhance aqueous solubility (and 
thus improve chromatographic properties) or to incorporate an affinity label.  For the former 
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purpose, 4-(aminomethyl)benzenesulfonic acid (ABS) was synthesized and tested with model 
systems (8).  For the latter purpose, (3R,4S)-1-(4-(aminomethyl)phenylsulfonyl)pyrrolidine-3,4-
diol (APPD) was synthesized and used to label model peptides and proteins prior to affinity-
based enrichment with a boronate-affinity HPLC method (1).  Benzylamine was the primary 
focus of the current project, which aimed to develop this method to label and identify 
endogenous modifications that accumulate in cardiac tissue during aging. 
2.2 Experimental Methods 
2.2.1 Materials 
Sodium dithionite (SDT), synonym sodium hydrosulfite, was purchased from Sigma-
Aldrich (St. Louis, MO, USA) as one of two product types: purified ≥86% (Riedel-de Haën) or 
technical grade, 85% (Sigma-Aldrich).  Ammonium bicarbonate; sodium iodoacetate, 
SigmaUltra; sodium phosphate dibasic ACS reagent (anhydrous); benzylamine, redistilled, 
99.5%+, which was stored in a sealed container protected from air, moisture and light and 
retrieved under positive pressure of argon to protect the stock from air exposure; trichloroacetic 
acid, electrophoresis reagent, minimum 99%; 2-mercaptoethanol; methanol, CHROMASOLV 
grade; acetone, CHROMASOLV®, for HPLC, ≥99.9%; albumin bovine serum, Fraction V, 
≥96%; Triton X-100; glycerol; a kit for molecular weights 12,000-200,000 for gel filtration 
chromatography; and potassium ferricyanide were all obtained from Sigma-Aldrich, St. Louis, 
MO, USA. 
 Sodium dodecyl sulfate (SDS), electrophoresis grade; sodium hydroxide, certified ACS; 
sodium phosphate monobasic, certified ACS (monohydrate); sodium sulfate, certified ACS 
(anhydrous); tris(hydroxymethyl)aminomethane hydrochl ride, for molecular biology; 
tris(hydroxymethyl)aminomethane crystallized free base, molecular biology grade; hydrochloric 
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acid, Certified ACS Plus; and urea, electrophoresis grade were all obtained from Fisher 
Scientific, Pittsburgh, PA, USA. 
Complete, EDTA-free protease inhibitor cocktail was purchased from Roche Diagnostics, 
Indianapolis, IN, USA. 
Ethanol, 99.90-100.00%, was from Decon Laboratories, Inc., King of Prussia, PA, USA. 
CHAPS 3-[(3-cholamidopropyl)dimethylamonio]-1-propanesulfonate; bicinchoninic acid 
(BCA) protein assay kit; zeba spin desalting columns, 7kDa molecular-weight cutoff, 0.5mL; 
and Coomassie Colloidal Blue stain were all from Thermo Scientific (Rockford, IL, USA). 
DL-dithiothreitol (DTT), molecular biology grade; and sequencing grade modified 
trypsin, porcine, specific activity >5,000U/mg were f om Promega, Madison, WI. 
 2X Laemmli sample buffer; 10X tris/glycine/SDS buffer for SDS-PAGE applications; 
Ready Gel® Tris-HCl, 4-20% precast linear gradient polyacrylamide gel, 10-well, 50µL, 8.6 x 
6.8 cm; and Precision Plus Protein Dual Color Standards were from Bio-Rad, Hercules, CA, 
USA. 
2.2.2 Extraction and Preparation of Cardiac Proteins 
 The research protocol for treatment of animals was approved by the University of Kansas 
Institutional Animal Care and Use Committee.  Fisher 344/BN F1 rats, an established model for 
biological aging, were housed under a 12:12 light-dark cycle and provided with food and water 
ad libitum.  Following decapitation of the young (5-6 months old) and old (34-36 months old) 
animals, the hearts were quickly harvested and frozen at -70°C until use.  Homogenates of this 
tissue were prepared in a lysis solution composed of 10mM tris(hydroxymethyl)aminomethane 
buffer with pH 7.4, 1% (v/v) Triton X-100 detergent, 1% glycerol, EDTA-free protease inhibitor 
cocktail at the manufacturer’s recommended concentration, 6M urea, and 8mM dithiothreitol 
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(DTT).  Heart tissue was sliced, added to lysis soluti n, and homogenized with an Ultra-Turrax 
T8 homogenizer (Fisher; Pittsburgh, PA).  After 10min incubation, with rocking, followed by 
centrifugation at 5,445×g for 30min at 4°C, the pellet of cellular debris was discarded and the 
protein-rich supernatant was added to an equal volume of reduction buffer, giving final 
concentrations of 10mM tris(hydroxymethyl)aminomethane buffer with pH 7.4, 1% (v/v) Triton 
X-100 detergent, 1% glycerol, EDTA-free protease inhibitor cocktail at the manufacturer’s 
recommended concentration, 3M urea, and 10mM dithiothreitol (DTT).  For the reductive 
alkylation of Cys, proteins were incubated in this reduction buffer for 30min at 55°C before 
adding 25mM sodium iodoacetate and reacting at room temperature for 30min.  Aliquots of this 
protein solution were cleaned by protein precipitation with cold EtOH, as described in section 
2.2.3.  Re-constitution buffers were typically at pH 7.4 and contained either sodium phosphate or 
ammonium bicarbonate with either SDS or CHAPS.  The exact buffer composition will be 
indicated in the text for individual experiments.  To aid dissolution, sonication by the probe 
sonicator Sonic Dismembrator 500 (Fisher Scientific, Pittsburgh, PA, USA) was typically 
performed with three pulses of 10s each at 20% power utput and one pulse of 10s at 40% power 
output, with breaks between pulses lasting a minimum of 10s.  Solutions were also typically 
warmed in a 37°C water bath for at least 30min.  Protein concentration in the final cardiac 
protein stock solution was determined by BCA assay ( ee section 2.2.4).  Stock solutions were 
aliquotted and stored at -70°C until use. 
2.2.3 Protein Precipitation for Removal of Reagents 
 In order to clean samples from derivatization reagents or other solution components, such 
as SDT, potassium ferricyanide, BA, and detergent, proteins were precipitated by one of the 
following methods.  For precipitation in cold ethanol (EtOH), ten solution volumes of 100% 
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ethanol was cooled to -20°C and added to the sample, which was promptly incubated either 
overnight at -20°C or for a minimum of 4h at -70°C.  Protein pellets were collected by 
centrifugation for 5min, the supernatant discarded, and fresh cold 100% EtOH added to wash the 
proteins.  This process was repeated for a total of three washes. 
 For precipitation in cold trichloroacetic acid (TCA), ten solution volumes of 22% (w/v) 
TCA was cooled on ice and added to the sample, givin  a final TCA concentration of 20% (w/v).  
Samples were incubated overnight on ice in a refrigrator maintained at approximately 4°C.  
Protein pellets were collected by centrifugation at for 5min, the supernatant discarded, and cold 
(-20°C) 100% acetone added to wash the proteins.  This process was repeated for a total of three 
washes. 
In either method, washed proteins were once more coll cted by 5min centrifugation and 
then allowed to air dry before re-constituting proteins in the buffer of choice.  As needed, the 
dissolution process was aided with sonication by the probe sonicator Sonic Dismembrator 500 
(Fisher Scientific, Pittsburgh, PA, USA) and/or by warming in a 37°C water bath. 
2.2.4  BCA Assay for Protein Concentration 
 Selected for its compatibility with several detergents, the BCA protein assay was 
conducted largely as recommended by the manufacturer’s protocol for the test tube procedure, 
with only minor adjustments.  Protein standards containing 2mg/mL bovine serum albumin 
(BSA) were prepared in-house in the same buffer as samples and serially diluted, following the 
manufacturer’s protocol, to produce calibration standards with final protein concentrations in the 
range 25-2,000µg/mL.  To 50µL of sample, diluted as needed to give a concentration within the 
assay’s working range, was added 1mL working reagent.  Samples were incubated in a water 
bath at 37°C for 20-30min.  This reaction time was periodically adjusted empirically to produce a 
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calibration curve with the largest possible linear range.  Absorbance at 562nm was measured for 
all calibration standards and samples, and a blank-corrected calibration curve was constructed 
and used to calculate sample protein concentrations, according to manufacturer’s instructions. 
2.2.5 Derivatization Reactions 
Since the conditions for both 3NY reduction to 3AY and fluorogenic labeling of 3AY and 
DOPA were the subject of many optimization experiments over time, details will be provided as 
needed alongside each set of data described. 
2.2.6  SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE (under reducing conditions) was performed using the Bio-Rad Mini-
PROTEAN® electrophoresis and blotting system (Hercul s, CA, USA).  Samples were mixed 
with an equal volume of 2X Laemmli sample buffer, which had been supplemented with 5% 
(v/v) 2-mercaptoethanol, and heated in a boiling water bath for 2min.  Samples and molecular-
weight markers were loaded into pre-cast 4-20% gradient gels and separated by electrophoresis 
in 1X tris/glycine/SDS run buffer at constant 200V for 38min, with maximum current limited at 
400mA.  Proteins were visualized by Coomassie Colloida  Blue staining. 
2.2.7  Size-Exclusion HPLC (SE-HPLC) 
SE-HPLC was performed on a Shimadzu 10A Series High-Performance Liquid 
Chromatograph (Kyoto, Japan).  The optimal method was as follows: an isocratic method using 
0.1M sodium phosphate plus 0.1M sodium sulfate, pH 6.8, as a mobile phase at a flow rate of 
1.0mL/min separated protein solutions on a Tosoh TSK-GEL G3000SWXL column, 7.8mm ID x 
30cm, 5µm particles.  The loop volume for the manual injector was 20µL, and 40µL protein 
solution was loaded in order to ensure complete loop filling.  Detection was by UV absorbance at 
280nm and fluorescence at excitation 360nm and emission 460nm.  This optimal method was 
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reached over time, and variations in the method usefor particular experiments will be described 
in the text as appropriate.  The method was periodically calibrated with protein molecular-weight 
standards in the range 12-200kDa and showed good linearity for a plots of log(molecular weight) 
vs. retention volume. 
2.2.8 Mass-Spectrometry-Based Proteomics 
Proteins were digested with trypsin overnight at 37°C, typically with a 1:20 molar ratio of 
trypsin:cardiac protein, as calculated using an estimated average molecular weight of 50kDa for 
cardiac proteins.  Samples containing tryptic peptides were analyzed by nano-HPLC-ESI-
MS/MS, as described previously (5,10).  Briefly, peptides were separated by nano-flow HPLC 
with columns (300 Å, 10cm × 75µm, 15µm tip size; New Objective, Woburn, MA) packed in-
house with BioBasic octadecyl stationary phase (Thermo Electron) and using a linear gradient of 
water and acetonitrile, both containing 0.1% formic acid, at a flow rate of 0.5µL/min.  
Chromatography was online with either a ThermoElectron LCQ Duo or a ThermoElectron 
Classic (San Jose, CA), equipped with a nanoelectrospray source (ThermoElectron). 
2.3 Results 
2.3.1 Optimal Conditions for Reduction of 3NY to 3AY 
 Since the amount of endogenous protein-bound 3NY present in cardiac homogenate 
samples is unknown, empirical evidence was used to determine the amount of SDT required to 
reduce 3NY to 3AY.  Concentrations of 1, 10, or 20mM SDT were reacted with 0.9mg/mL 
cardiac proteins from a young rat (in 0.1M pH 7.4 sodium phosphate buffer with 4% CHAPS) 
for 0.75, 1.5, 2, 15, or 30min at room temperature before precipitation by cold ethanol (see 
section 2.2.3).  Derivatization was carried out in 0.1M pH 9 sodium phosphate buffer plus 4% 
CHAPS with 0.7mg/mL protein, 1mM potassium ferricyanide, and 460mM BA for 2.5h at room 
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temperature in the dark.  Fluorescence 
measurements at excitation and emission 
wavelengths of 360 and 460nm, respectively, 
were conducted using the SpectraMax Gemini 
XS Dual-Scanning Microplate 
Spectrofluorometer (Molecular Devices 
Corporation, Sunnyvale, CA, USA) running 
SOFTmax® PRO Version 4.0 software for 
Windows ®, with the following settings: 
emission cutoff 455nm, 18 reads, PMT 
sensitivity auto, automix 5s before, and auto 
calibrate on. 
 Increasing SDT concentrations 
consistently increased the yield of fluorescent 
product, regardless of the reduction reaction 
time (Fig. 2.1).  Importantly, reduced and 
derivatized samples showed greater fluorescence than controls in which either SDT or protein 
were omitted.  For future experiments, 10-20mM SDT for 1.5-2min was selected as the method 
of choice, at least when similar protein concentrations were used. 
2.3.2 Derivatization Reagent Concentration Dependences 
 Cardiac proteins from an old rat were prepared at a concentration of 8.0mg/mL in 0.1M 
pH 7.4 sodium phosphate buffer with 0.5% SDS.  For reduction of 3NY to 3AY, proteins were 
exchanged into 0.1M pH 5 sodium acetate buffer with0.5% SDS by zeba spin cartridges, 
Fig. 2.1  Dithionite concentration 
dependence for cardiac proteins tagged with 
BA.  Cardiac proteins from a young rat 
(0.9mg/mL in 0.1M pH 7.4 sodium 
phosphate buffer with 4% CHAPS) were 
reduced with 1, 10, or 20mM SDT for 0.75, 
1.5, 2, 15, or 30min before precipitation in 
cold ethanol.  Derivatization was carried out 
in 0.1M pH 9 sodium phosphate buffer plus 
4% CHAPS with 0.7mg/mL protein, 1mM 
potassium ferricyanide, and 460mM BA for 
2.5h at room temperature in the dark. 
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according to the manufacturer’s buffer exchange protocol.  Reduction with 10mM SDT and 
~6.9mg/mL protein was carried out for 37°C for 15min, a d the samples remained at room 
temperature for about an hour during preparation for the next step.  Another buffer exchange was 
performed with zeba cartridges into the tagging buffer, 0.1M pH 9 sodium phosphate with 0.5% 
SDS.  Derivatization of ~3.5mg/mL protein was performed with a range of reagent 
concentrations, designed as a matrix to test all possible combinations.  Potassium ferricyanide 
was tested in the range 50µM-5mM with either 0-36mM BA or 0-36mM APPD.  Reaction 
progress was followed over time by fluorescence in a plate reader with the following settings: 
excitation/emission wavelengths 360/510nm with cutoff 495nm (for APPD) and 360/455nm with 
cutoff 435nm (for BA), 18 readings, PMT sensitivity auto, automix 5s, autocalibrate on.  Various 
control samples were also included, and background correction was performed for labeled 
protein samples, where indicated, by subtracting the fluorescence intensity of controls lacking 
protein but containing buffer and all reagents.  APPD in particular had rather high background 
fluorescence in this control. 
Fig. 2.2 shows both time course data and reagent concentration dependence curves.  BA 
reactions produced higher fluorescence intensities than APPD samples, but both sets of reactions 
were largely complete after 60-100min reaction time.  Potassium ferricyanide dependence shows 
a plateau or peak beginning at 1mM.  BA dependence is optimal at 18mM for several samples.  
APPD shows increasing fluorescence intensity through t the concentration range tested, with 
the upper limit being 20mM.  However, after background correction, this trend reverses, and the 
greatest fluorescence intensity is observed for 5mM APPD.  The sample containing non-reduced 
proteins with 5mM potassium ferricyanide and 18mM BA seems to be an aberration and may be 
due to experimental error in sample preparation. 
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Fig. 2.2 Fluorescence data for optimization of 
reagent concentrations. Time course for selected 
BA (a) and APPD (b) reactions, with background 
correction (subtract fluorescence from controls 
lacking protein but containing reagents).  
Concentration dependence curves after 105min 
reaction time for PF with BA (c) and APPD (d), 
and for BA (e) and APPD (f) without correction 
and for APPD with background correction (g).  
PF: potassium ferricyanide, BA: benzylamine 
a b 
c d 
e f 
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 The greater solubility of BA in water enabled testing of much larger concentrations, as 
well.  Previous studies with model systems (6,9) supported use of such high excesses of BA over 
analyte.  Cardiac proteins from a young rat were lab led without reduction, thus focusing on 
labeling DOPA.  To 0.7mg/mL protein in 0.1M pH 7.4 sodium phosphate buffer with 4% 
CHAPS was added potassium ferricyanide in concentrations of the range 10µM-5mM and BA 
ranging 2-460mM, once again designed as a matrix to test all possible combinations.  While the 
protein remained in a buffer solution at pH 7.4 for this experiment, the alkaline properties of BA 
[pKa = 9.32 (7)] are likely to dominate the solution conditions, especially at such high BA 
concentrations.  Reaction progress was followed over time by fluorescence endpoint 
measurements in a plate reader with the following settings: excitation/emission wavelengths 
360/450nm, cutoff 435nm, 18 readings, PMT sensitivity auto, automix 5s, autocalibrate on.  
Controls lacking protein but containing all buffer and reagents were used for background 
correction, where indicated, by subtracting their fluorescence intensity from that of their labeled 
counterparts. 
 Fig. 2.3 shows most reactions are largely complete after 180min (a), at which time the 
background-corrected fluorescence intensity shows a maximum at 100µM potassium 
ferricyanide (b) and a plateau at 100mM BA (c).  All data in Fig. 2.3 are background-corrected. 
2.3.3 Comparison of Cleaning Procedures 
 As an optimization effort, variations in SDT reduction time and post-reduction cleaning 
methods were tested for protein recovery, based on BCA assay (see section 2.2.4), and tagging 
efficiency, as measured by fluorescence intensity.  Cardiac proteins were prepared to 1.2-
1.3mg/mL in 0.1M pH 7.4 sodium phosphate buffer with 4% (w/v) CHAPS and reduced with 
10mM SDT for either 1.5min or 15min.  Non-reduced samples were simultaneously prepared 
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and exposed to all steps of the protocol, except for the omission of SDT.  All samples were 
cleaned by precipitation protocols using either EtOH or TCA (see section 2.2.3) and re-
constituted in 0.1M pH 9 sodium phosphate buffer with 4% (w/v) CHAPS, with probe sonication 
for 5s at 10% power output.   For labeling, approximately 0.9mg/mL protein (assuming 100% 
recovery from reduction and cleaning) was reacted with 1mM potassium ferricyanide and 
250mM BA for 1h at room temperature in the dark.  Fluorescence was measured by plate reader 
with the following settings: excitation/emission wavelengths 366/455nm, cutoff 420nm, 6 reads, 
PMT medium, automix 5s, autocalibrate on.  After approximately 2h total reaction time, sample 
aliquots were taken for analysis by SDS-PAGE (see section 2.2.6), and the remainder of each 
Fig. 2.3 Fluorescence data for optimization of 
reagent concentrations. Time course for selected 
reactions (a) and concentration dependence 
curves for potassium ferricyanide (b) and BA (c) 
after 181min reaction time.  All data have been 
background-corrected by subtraction of 
fluorescence from controls lacking protein but 
containing reagents. 
a 
b c 
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sample was again cleaned by precipitation with either e EtOH or TCA protocol, with re-
constitution in 0.1M pH 9 sodium phosphate with 4% (w/v) CHAPS.  These cleaned samples 
were analyzed for protein concentration by 
the BCA assay (see section 2.2.4). 
While reduction time did not have a 
significant effect on either of these 
parameters, precipitation by TCA showed 
superior performance to EtOH, leading to 
higher fluorescence intensities upon labeling 
cardiac proteins with BA (Fig. 2.4) and to 
greater protein recovery (Table 2.1).  This 
experiment was conducted twice, and the 
fluorescence data was averaged in Fig. 2.4.  
However, accurate protein recovery data was 
not obtained from the first sample set due to 
experimental errors, in particular a poor 
calibration in the BCA protein concentration 
Fig. 2.4  Comparison of protein precipitation 
methods and reduction reaction times, based 
on fluorescence intensity of proteins after 
labeling.  Approximately 1mg/mL cardiac 
protein was reduced with 10mM SDT and 
cleaned by either EtOH or TCA precipitation 
protocols.  After re-constitution in 0.1M pH 9 
sodium phosphate buffer with 4% (w/v) 
CHAPS, proteins were labeled with 1mM 
potassium ferricyanide and 250mM BA for 
1h before measuring fluorescence using a 
plate reader. 
0
500
1000
1500
2000
2500
3000
No
Reduction
1.5min
Reduction
15min
Reduction
F
lu
or
es
ce
nc
e 
In
te
ns
it
y
(3
66
/4
55
nm
, a
u)
EtOH
TCA
Table 2.1  Protein recovery data and normalization of fluorescence intensities to protein 
concentrations for comparison of protein precipitation methods and reduction reaction times. 
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assay.  Thus, Table 2.1 presents data from a single exp riment, but the results are consistent with 
similar experiments performed in the course of thisproject, one of which is described in section 
3.2.4.  Multiple control samples were also included in this experiment, and the average recovery 
from all protein-containing samples was 63% ± 27% for the EtOH method and 87% ± 7% for 
TCA method (n=12 for each method).  Controls lacking protein but containing all reagents and 
buffer components for the labeling reaction contained solid material following EtOH 
precipitation, indicating the incomplete removal of these substances, which could potentially 
interfere with subsequent steps. 
In order to qualitatively compare protein recovery p ofiles, samples were separated by 
SDS-PAGE and visualized using Coomassie Brilliant Blue (Fig. 2.5).  Based on protein 
concentration data from the BCA assay, protein loads were equalized to 15.2µg for each sample.  
For two samples, this was not possible: lane 6 contains only 8.5µg and lane 10 13.6µg.  Each 
sample shows qualitatively equal amounts of protein (accounting for the lower protein loads in 
lanes 6 and 10) and a consistent pattern of 
bands.  Thus, the data indicate that the choice 
of protein precipitation method does not affect 
the composition or integrity of protein 
recovered, but rather only the amount.  It was 
surprising to see that the majority of proteins 
present in all samples, including stock cardiac 
proteins (lane 2) were of molecular weight 
less than 50kDa.  This may be due to 
incomplete re-constitution during the 
Fig. 2.5  SDS-PAGE stained with Coomassie 
Blue for comparison of protein precipitation 
methods and reduction reaction times. Each 
lane 2-10 contains 15.2µg cardiac protein 
(based on BCA protein concentration assay), 
unless marked (*).  Lane 1: molecular-weight 
markers; lane 6: 8.5µg cardiac protein; lane 
10: 13.6µg cardiac protein. 
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preparation of the cardiac homogenate.  Particularly, CHAPS is much less efficient than SDS for 
solubilizing cardiac proteins, as indicated by typical final protein concentrations of 1.0-
1.5mg/mL with the former and 10mg/mL with the latter. 
Significantly, the EtOH precipitation method seems to be biased against recovery of 
proteins that are not exposed to SDT (i.e., “no reduction” samples).  Such a bias could lead to the 
inaccurate conclusion that samples reduced by SDT (when cleaned by EtOH precipitation) have 
increased labeling, presumably representing significant levels of 3NY.  However, the ratio of 
fluorescence intensity to protein concentration is very similar for samples with and without SDT 
reduction, for both cleaning methods.  In addition, controls containing all reaction components 
except for BA showed higher fluorescence in samples exposed to SDT than in “no reduction” 
samples, but only when the EtOH precipitation method was used.  This may also be connected to 
poor protein recovery in the latter, suggesting a possible reaction of potassium ferricyanide with 
protein.  Previous work with similar derivatization chemistry has suggested the oxidation of Trp 
residues to kynurenin and related compounds, leading to background fluorescence (8). 
Section 2.3.5 explores further the comparison of samples with and without SDT 
reduction, and it should be noted that for those experiments, the “no reduction” or “DOPA” 
samples did not undergo any cleaning procedure and so are not subject to this artifact.  The cause 
of this potential bias remains unknown, and different xperimental conditions have given 
variable results regarding the effect of SDT reduction on the yield of fluorescent product from 
labeled cardiac proteins.  Section 2.3.5 represents the most effective investigation of this topic. 
2.3.4 Comparison of Young and Old Rats 
 Cardiac proteins from young or old rats were prepad to 1.4mg/mL in 0.1M pH 7.4 
sodium phosphate buffer with 4% (w/v) CHAPS and acidified with hydrochloric acid to an 
68 
 
estimated pH 5.  For each age, one sample was reduced with 20mM SDT for 30min at room 
temperature and the other was treated similarly, except for the omission of SDT.  Desalting by 
zeba spin cartridges was followed by sonication in a water bath for 10min, which failed to 
completely solubilize all proteins.  Supernatants were collected and labeled with an estimated 
protein concentration 0.6mg/mL and reagent concentrations 1mM potassium ferricyanide and 
460mM BA for 3h at room temperature in the dark.  Reaction progress was measured by 
fluorescence plate reader with the following settings: excitation/emission wavelengths 
360/460nm, cutoff 455nm, 18 readings, PMT sensitivity auto, automix 5s, and autocalibrate on.  
Samples were again desalted with zeba cartridges to avoid fouling the SE-HPLC column with 
excess reagents.  SE-HPLC analysis was conducted as described in section 2.2.7.  Both the 
fluorescence intensity and SE-HPLC data shower greater yields of fluorescently-labeled proteins 
for old samples compared to young samples and for reduced samples compared to young 
samples (Fig. 2.6).  These results are consistent with increased levels of both DOPA and 3NY in 
cardiac tissue from old animals and with the successful reduction and labeling of 3NY in reduced 
samples, while only DOPA is labeled in non-reduced samples.  
a Fig. 2.6  Comparison of cardiac proteins 
from old and young rats derivatized with BA, 
with or without prior reduction of 3NY to 
3AY by SDT.  Reaction time course, with 
background correction (a), comparisons of 
SE-HPLC chromatograms for old rat proteins 
with or without reduction (b), young rat 
proteins with or without reduction (c), and 
comparisons of SE-HPLC chromatograms 
for reduced samples of both ages, (d) and 
non-reduced samples of both ages (e).  The 
dotted lines running through the 
chromatograms mark the retention volumes 
of molecular-weight standards. 
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  Fig. 2.6b 
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Fig. 2.6c 
 
stock proteins, young 
young, reduced stock 
young, not reduced stock 
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control: no protein 
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Fig. 2.6d 
stock proteins, old 
stock proteins, young 
old, reduced stock 
young, reduced stock 
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old, reduced, control: no BA 
young, reduced, control: no BA 
control: no protein 
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Fig. 2.6e 
 
stock proteins, old 
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old, not reduced stock 
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old, not reduced, control: no BA 
young, not reduced, control: no BA 
control: no protein 
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2.3.5 Comparison of Reduced and Non-Reduced Samples 
 Proteins from old and young rats were prepared with equal concentrations, 1.4mg/mL, in 
0.1M pH 7.4 sodium phosphate buffer with 4% (w/v) CHAPS.  To tag only DOPA, samples in 
the “no reduction” experiment did not undergo any further treatment before benzylamine 
derivatization.  To tag 3NY in addition to 
DOPA, 1.3mg/mL protein was reduced with 
20mM SDT for 30min at room temperature 
and then cleaned by zeba spin cartridge.  For 
both sample sets, 0.7mg/mL protein was 
derivatized with 1mM potassium ferricyanide 
and 460mM BA for 3h at room temperature in 
the dark.  Fluorescence was measured by plate 
reader with the following settings: 
excitation/emission wavelengths 360/460nm, 
cutoff 455nm, 18 reads, PMT sensitivity auto, 
automix 5s, autocalibrate on. 
 As shown in Fig. 2.7, reducing 
proteins with SDT before tagging produced 
much higher fluorescence intensities, 
consistent with labeling of only DOPA in non-reduced samples and both DOPA and 3NY in 
reduced samples.  The age of the rat did not significa tly affect the fluorescence intensity for 
reduced samples in this particular experiment, but there is a statistically significant difference 
between the ages in the non-reduced samples, with the young sample having greater fluorescence 
Fig. 2.7 Cardiac proteins from old or young 
rats, 1.3mg/mL in 0.1M pH 7.4 sodium 
phosphate with 4% CHAPS, were either 
untreated (DOPA) or reduced with 20mM 
SDT for 30min and desalted with zeba spin 
columns (DOPA + 3NY).  All samples were 
then labeled at concentrations of 0.7mg/mL 
protein, 1mM potassium ferricyanide, and 
460mM benzylamine for 3h in the dark.  
Fluorescence was measured by plate reader 
at the excitation/emission wavelengths 
360/460nm. **p<0.01, ****p<0.001 
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than the old sample.  A two-tailed unpaired Student’s t-test was used to calculate all p-values.  It 
is not entirely clear why an age-dependent difference was observed in the previous experiment 
but not in this one, but the inconsistency may be du  to slight changes in experimental conditions 
and/or different tissue homogenate preparations from different animals.  Furthermore, statistical 
analysis was not performed for the previous experimnt, since it represents only a single sample. 
Note that in the current experiment, non-reduced samples were not subjected to any 
cleaning steps before the labeling reaction and thus are not subject to the potential artifact 
described in section 2.3.3.  The SE-HPLC-UV data, described below, provides further analysis of 
the protein content in both non-reduced and reduced samples.  All samples were cleaned with 
zeba desalting spin columns after approximately 4h total reaction time before SE-HPLC, in order 
to avoid damaging the column with excess reagents.  Sonication was used to help dissolve 
precipitated proteins after this cleaning step. 
 The SE-HPLC chromatograms, shown in Fig. 2.8, clearly show the increased 
fluorescence of reduced samples compared to non-reduced samples, with the major fluorescent 
peaks eluting in the molecular-weight range >10kDa.  In the UV chromatograms, the reduced 
samples also have slightly higher signals than non-reduced samples.  Figures 2.8c and 2.8d show 
the quantitative comparison based on peak areas, which ere integrated only in the molecular-
weight region corresponding to protein.  Note that retention times shifted slightly between the 
non-reduced and reduced experiments, likely due to column fouling by sample materials over 
time.  Although SE-HPLC is designed to work only by size-based mechanisms, other 
interactions between analytes and the stationary phase can occur, particularly hydrophobic 
interactions (11).  This secondary separation mechanism can become more pronounced if 
hydrophobic sample materials are not completely eluted from the stationary phase.  For this 
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reason, retention time ranges for peak integration were selected based primarily on peak shape, 
in comparison to previously observed patterns, rather t an strictly on the times themselves.  
Various controls are included, as are peak areas for UV chromatograms (Fig. 2.8d) 
corresponding to the same retention time ranges that were integrated for the fluorescence data, in 
order to account for possible differences in protein concentrations.  The SE-HPLC peak area data 
Fig. 2.8  Comparison of SE-HPLC peak areas for labeled cardiac proteins from old and young 
rats, with (DOPA + 3NY) or without (DOPA) prior reduction by SDT.  (a) Averaged FL 
chromatograms (triplicate), (b) Averaged UV chromatograms (triplicate), (c) FL peak areas, 
and (d) UV peak areas.  *p<0.05, ***p<0.005, ****p<0.001 
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show much greater fluorescence for cardiac proteins that were reduced before tagging than for 
those not reduced, once again demonstrating the effect o  labeling 3NY in addition to DOPA and 
suggesting that a significant amount of the former exists in the cardiac samples.  A two-tailed 
unpaired Student’s t-test was used to calculate all p-values. 
2.3.6 Putative Protein Identifications 
 Fig. 2.9 shows MS/MS spectra that have been assigned by the proteomic search 
algorithms to BA- or ABS-labeled tryptic peptides from the rat protein sequence database.  
While these are putative identifications of endogenous Tyr nitration sites, the spectral quality and 
assignments are not sufficient to support confident identification. 
2.4 Discussion and Conclusions 
 The effects of various conditions for sample prepaation and derivatization reactions have 
been studied for the fluorogenic labeling of protein-bound 3NY and DOPA in cardiac tissue 
homogenates.  While the multidimensional nature of the optimization process has produced data 
with sometimes inconsistent results and trends, likely affected by changes of multiple conditions 
between experiments, several systematic studies have yielded informative results for method 
development.  These include reduction conditions with 10-20mM SDT for 1.5-2min to convert 
3NY to 3AY, with the results being more dependent on SDT concentration than on reaction time.  
Experiments with model systems have indicated side product formation with long reaction times 
and high SDT concentrations (Victor Sharov, unpublished results).  Since this phenomenon is 
difficult to measure directly in the more complex cardiac samples, it is best to use the minimal 
SDT concentration and reaction time necessary to give sufficient product yield, as measured by 
fluorescence intensity.  The dependence of fluorescence intensity on derivatization reagent 
concentrations has also been studied, and the optimized conditions applied to compare samples  
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from old and young rats as well as samples tagged for DOPA only (non-reduced) with those 
tagged for DOPA plus 3NY (reduced).  While several xperiments demonstrate significant 
increases in labeling for reduced samples relative to non-reduced and for old relative to young, 
these results could not always be reproduced in follow-up experiments.  Differences in sample 
preparation conditions may contribute to this inconsistency.  For instance, comparison of protein 
precipitation methods for cleaning reagents away from cardiac proteins revealed that the EtOH 
method may have a bias against protein recovery in samples not reduced by SDT, whereas the 
TCA method has no such bias and does not show a significant difference in fluorescence for 
these two sample sets, either.  Animal-to-animal variability is also an important consideration in 
working with biological samples, and larger sample sizes, for instance using at least 3 animals in 
each age group, could provide a more definitive answer to the question of whether PTM 
accumulation occurs with aging, or at least whether such accumulation is detectable by this 
method.  Tighter quality control for consistency betw en preparations of cardiac homogenates 
(for instance, by SDS-PAGE analysis) and for proper function of the HPLC instrument would 
also help to minimize variability. 
 Ultimately, the goal of this labeling method is the proteomic identification, by mass 
spectrometry, of oxidized proteins in aging cardiac t ssue.  Since these PTMs are in low 
abundance in vivo, it is crucial that the labeling method is as complete and as selective as 
possible.  While searches of nano-HPLC-MS/MS data against the rat proteome database have 
produced some putative identifications of modified proteins, the sample complexity demands a 
high standard of spectral quality for confident identification, in order to avoid false positives.  
Under the current conditions, such confidence has not been achieved.  Moving forward, one 
strategy planned to progress toward this goal is the implementation of ultra-high-performance 
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liquid chromatography on a 2m-long capillary column on-line with the electrospray source for 
mass spectrometry.  This method is capable of dramatically improving chromatographic column 
capacity and resolution for tryptic peptides, which in turn reduces ion suppression effects from 
the overwhelming matrix of unmodified cardiac peptides and thus enhances the signal for low-
abundance modified peptides.  Another approach to minimize this ion suppression and other 
interferences is to enrich labeled peptides using the reagent APPD with boronate-affinity HPLC.  
Finally, in order to overcome limitations due to the suspected low analyte concentrations, 
nitration of cardiac proteins in vitro by peroxynitrite could provide samples with sufficient levels 
of 3NY to enable effective identification as a proof f concept and to provide a more effective 
platform for method optimization studies. 
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Chapter 3:  Derivatization of Glycogen Phosphorylase b Protein Nitrated in 
vitro 
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3.1  Introduction 
3.1.1  Glycogen Phosphorylase b as a Target of Tyrosine Nitration  
Glycogen phosphorylase b (Ph-b) has previously been identified as a target of tyrosine 
nitration both in vivo (for instance, as a result of aging) and i  vitro (2,11,12).  With a total 
molecular weight of 97kDa, it contains 842 amino acids, 36 of which are Tyr (4.3%).  This 
enzyme is an important part of glucose metabolism, converting glycogen to glucose-1-phosphate 
(2,11).  It comprises approximately 5% of total soluble protein in skeletal muscle tissue (11), and 
its functional impairment leads to deficits in muscle function and metabolic myopathy, such as 
McArdle’s disease (2,11,12).  This protein has >95% homology across mammalian species and 
98% homology among rabbit, mouse, and human amino acid sequences.  In a previous study, 
Sharov et al. (10) identified by HPLC-MS/MS sequencing 11 unique in-vitro nitration sites 
labeled with the benzylamine derivative 4-(aminomethyl)benzenesulfonic acid.  Ph-b nitrated in 
vitro by peroxynitrite was selected as a model nitro-protein to spike into cardiac homogenate 
samples in order to study the effectiveness of the APPD derivatization strategy within this 
complex matrix. 
3.1.2  “Denitration” 
The site-specific accumulation of 3NY in disease and ging results from a combination of 
processes that generate 3NY and those that repair or remove it (1,9).  Both types of processes can 
be specific or preferential for particular proteins and particular Tyr residue locations.  The 
formation of 3NY can depend on the nitrating agent, cellular localization, protein conformation 
(especially as it affects the solvent accessibility of Tyr), neighboring amino acids, and 
interactions of the protein with other proteins or small molecules, particularly metals (1,9).  The 
loss of 3NY can occur by proteolytic degradation (turnover) of damaged proteins or by 
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“denitration” processes that have been proposed but are not yet clearly understood (1); both of 
these can have protein or site selectivity.  The balance of all of these factors also helps to explain 
the differences often observed between nitration patterns in vivo and in vitro. 
Incubation of nitrated proteins with various biological matrices has been shown to 
decrease 3NY levels by a process that is dependent on time, concentration, and temperature, as 
summarized here based on a review by Abello, et al. (1).  This phenomenon persists in the 
presence of a proteasome inhibitor.  It has been report d to be sensitive to heat, trypsin, and 
peroxynitrite treatments and is inducible by lipopolysaccharide.  Filtration with a 10kDa-cutoff 
membrane did not destroy the activity in one case, but dialysis reduced it by 70% in another.  In 
some cases, denitration is dependent upon oxygen tension.  Calcium dependence has been 
reported in some systems, accompanied by nitrate ion formation.  In addition to the hypothesis of 
an enzymatic system, heme-bound Fe3+ plus a reducing agent like dithiothreitol (a common 
additive in homogenate preparations) is capable of r moving 3NY by reducing it to 3AY, as is 
cobalt-containing cyanocobalamin.  No enzymatic system has been identified, and the exact 
nature of this phenomenon – or, more likely, combination of phenomena – is still unclear. 
Products of denitration have been identified as 3AY and native Tyr, but other products 
are also possible (1,9).  Importantly, the formation of 3AY makes these residues undetectable by 
immunoaffinity methods but does not interfere with fluorogenic derivatization by benzylamine 
or its derivatives. 
3.2  Experimental Methods 
3.2.1  Materials 
Ammonium bicarbonate; sodium iodoacetate, SigmaUltr; sodium dithionite (SDT), 
synonym sodium hydrosulfite, technical grade, 85%; sodium phosphate dibasic ACS reagent 
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(anhydrous); benzylamine, redistilled, 99.5%+, which was stored in a sealed container protected 
from air, moisture and light and retrieved under positive pressure of argon to protect the stock 
from air exposure; trichloroacetic acid, electrophoresis reagent, minimum 99%; 2-
mercaptoethanol; methanol, CHROMASOLV grade; acetone, CHROMASOLV®, for HPLC, 
≥99.9%; albumin bovine serum, Fraction V, ≥96%; and potassium ferricyanide were all obtained 
from Sigma-Aldrich, St. Louis, MO, USA.  Ponceau S was also purchased from Sigma-Aldrich 
and prepared as a 0.5% (w/v) solution with 5% acetic ac d. 
 Sodium dodecyl sulfate (SDS), electrophoresis grade; sodium hydroxide, certified ACS; 
sodium phosphate monobasic, certified ACS (monohydrate); sodium sulfate, certified ACS 
(anhydrous); tris(hydroxymethyl)aminomethane hydrochl ride, for molecular biology; sodium 
chloride, certified ACS; hydrochloric acid, Certified ACS Plus; Millipore Immobilon-P 
polyvinylidene fluoride (PVDF) transfer membranes, 0.45 µm pore size; Tween 20, enzyme 
grade; Whatman 3MM Chr chromatography paper; GE Healthcare Amersham ECL Plus Western 
blotting detection system; and Kodak GBX developer and fixer solutions were all obtained from 
Fisher Scientific, Pittsburgh, PA, USA. 
 Phosphorylase b (rabbit muscle), 39.9% protein, balance predominantly lactose was from 
Prozyme, Hayward, CA. 
 DL-dithiothreitol (DTT), molecular biology grade; and sequencing grade modified 
trypsin, porcine, specific activity >5,000U/mg were f om Promega, Madison, WI. 
Ethanol, 99.90-100.00%, was from Decon Laboratories, Inc., King of Prussia, PA, USA. 
CHAPS 3-[(3-cholamidopropyl)dimethylamonio]-1-propanesulfonate; bicinchoninic acid 
(BCA) protein assay kit; Slide-A-Lyzer MINI dialysis units, 7kDa molecular-weight cutoff; zeba 
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spin desalting columns, 7kDa molecular-weight cutoff, 0.5mL; and goat anti-mouse HRP 
secondary antibody were all from Thermo Scientific (Rockford, IL, USA). 
Amicon Microcon YM-10 centrifugal concentrators with regenerated cellulose 
ultrafiltration membranes, 10kDa molecular-weight cutoff, were from EMD Millipore, Billerica, 
MA, USA. 
 2X Laemmli sample buffer; 10X tris/glycine/SDS buffer for SDS-PAGE applications; 
Ready Gel® Tris-HCl, 4-20% precast linear gradient polyacrylamide gel, 10-well, 50µL, 8.6 x 
6.8 cm; Precision Plus Protein Dual Color Standards; and 10X TG tris/glycine buffer were from 
Bio-Rad, Hercules, CA, USA. 
 Monoclonal antibody to nitrotyrosine, mouse IgG2b, was purchased from GenWay 
Biotech, Inc., San Diego, CA, USA. 
 Classic blue autoradiography film BX was from MIDSCI, St. Louis, MO. 
3.2.2  Preparation and Nitration of Ph-b 
 Ph-b was dissolved in 50mM ammonium bicarbonate buffer at pH 8 with 1% (w/v) SDS 
to a protein concentration of 1mg/mL (approximately 10µM).  Cys residues were reduced with 
2mM DTT for 30min at 50°C and alkylated with 5mM sodium iodoacetate for 30min at room 
temperature.  Ten volumes of cold 100% ethanol were added and the solution incubated for four 
hours at -70°C to precipitate the proteins.  Following centrifugation for 5min at 5,445×g, the 
supernatant was discarded and the pellet re-constituted in 50mM ammonium bicarbonate buffer 
at pH 8 with 1% (w/v) SDS.  Aliquots of the prepared protein were stored at -20°C until use.  
“Control” Ph-b proteins were used as is, whereas “3NY-Ph-b” proteins were prepared by treating 
these aliquots with peroxynitrite. 
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 Peroxynitrite was prepared according to a previously published method for the ozonolysis 
of sodium azide solutions (7) and stored in alkaline solution at -70°C.  Prior to each use, aliquots 
were thawed on ice, and the peroxynitrite concentration was measured by absorbance of a diluted 
solution prepared in 0.1% sodium hydroxide, using ε302 = 1,670M
-1cm-1 (7) in order to account 
for its gradual degradation during storage.  Approximately 3mM final concentration of 
peroxynitrite was added to 1mg/mL (approximately 10µM) Ph-b by placing a droplet of 
peroxynitrite solution on the side of the microcentrifuge tube and vortexing quickly.  This 
technique is important for ensuring relatively even distribution of reactive peroxynitrite in the 
protein solution because it degrades very quickly at pH 8 (7).  In order to determine the extent of 
nitration in each sample, 3NY concentration was determined based on its absorbance at 430nm 
with ε430 = 4,400M
-1cm-1 when pH is above 9 (5,10).  Specifically, solutions of both control Ph-b 
and 3NY-Ph-b were prepared in 0.1% sodium hydroxide, and the absorbance value at 430nm for 
the former was subtracted from that of the latter.  This corrected absorbance value was used to 
calculate 3NY concentration based on Beer’s law: 
 
   
Eq. 3.1 
where A is absorbance, ε is molar absorptivity (i.e., extinction coefficient), b is the path length, 
and c is the concentration of the absorbing species.  Aliquots of 3NY-Ph-b were stored at -20°C 
until use and sometimes required brief sonication to dissolve precipitates that formed upon 
freezing and storage, typically for 5s at 10-15% power output of the probe sonicator Sonic 
Dismembrator 500 (Fisher Scientific, Pittsburgh, PA, USA). 
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3.2.3  Derivatization Reaction 
 3NY-Ph-b at a concentration of 8µM and carrying approximately 16 mol 3NY per mol of 
protein (in 50mM ammonium bicarbonate buffer, pH 8, with 1% w/v SDS) was reduced with 
10mM SDT for 2min at room temperature and then immediat ly precipitated by 10 volumes of 
cold 100% ethanol at -70°C for 3h.  After centrifugation at 13,000×g for 2min, the supernatant 
was discarded and the pellet re-constituted in 0.1M sodium phosphate buffer at pH 9 with 4% 
(w/v) CHAPS detergent, using sonication for 5s at 15% power output.  The zwitterionic 
detergent CHAPS was selected because SDS was found t  cause large amounts of precipitation 
in tagging samples, especially when the pH was decreased in subsequent steps (e.g., size-
exclusion HPLC, SE-HPLC).   This is presumably due to ion pairing between the negatively 
charged SDS detergent and the large excesses of prot nated benzylamine reagent, pKa = 9.32 (6). 
 Fluorogenic derivatization was carried out with 0.5µM Ph-b (8µM 3NY), 1mM 
potassium ferricyanide, and 5% (v/v) benzylamine (= 458mM).  Reactions proceeded in the dark 
at room temperature for various lengths of time.  Some experiments monitored reaction progress 
based on fluorescence emission intensity with excitation and emission wavelengths 360nm and 
460nm, respectively, using a Shimadzu RF 5000U Spectrofluorophotometer (Kyoto, Japan) set 
to high sensitivity.  Fluorescence excitation and emission spectra were also collected with this 
instrument at high sensitivity, using 460nm as the emission wavelength for the former and 
360nm as the excitation wavelength for the latter. 
 Multiple controls were included in these experiments, including 3NY-Ph-b not exposed 
to SDT (i.e., non-reduced).  For both the reduced and non-reduced Ph-b samples, controls 
omitting either potassium ferricyanide or benzylamine from the derivatization reaction were 
included.  Finally, a sample containing no protein but with all other components of the 
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derivatization reaction (buffer, potassium ferricyanide, benzylamine) were measured.  These 
samples were also analyzed by SE-HPLC (see section 3.2.5). 
3.2.4  Determining the Limit of Detection (LOD) for 3NY-Ph-b in a Background of Cardiac 
Proteins 
 After about 1h reaction time, derivatized Ph-b was precipitated by addition of at least 10 
volumes 100% ethanol and overnight incubation at -20°C.  After centrifugation, the labeled 
protein was re-constituted in 0.1M sodium phosphate buffer at pH 7.4 with 4% (w/v) CHAPS 
(protein dissolution was slow).  Serial dilutions of labeled Ph-b mixed with a constant amount of 
cardiac protein solution (see section 2.2.2) were prepared and their fluorescence spectra collected 
as described in section 3.2.3.  These samples were also analyzed by SE-HPLC (see section 
3.2.5). 
 In order to provide a more accurate assessment of the tagging efficiency for proteins 
within the cardiac homogenate matrix, 3NY-Ph-b and control Ph-b were added to cardiac 
samples in ratios designed to keep the total Ph-b and c rdiac protein concentrations constant 
while varying the concentration of 3NY on Ph-b.  Next, the Ph-b plus cardiac mixtures were 
subjected to the reduction and derivatization procedur s, which will be described below.  This 
experiment was conducted in duplicate to assess variability.  A few adjustments to the labeling 
protocol were made for optimization purposes.  Precipitation by ethanol was replaced with 
trichloroacetic acid (TCA), namely the addition of ten volumes of cold aqueous TCA to give a 
final acid concentration of 20% (w/v).  Samples were incubated overnight on ice in a refrigerator 
maintained at 4°C.  Pellets were collected by centrifugation at 5,445×g for 5min and washed 
three times with 5mL cold acetone to remove any remaining traces of TCA.  This precipitation 
method was shown to improve cardiac protein recovery to 96%, compared to 51% recovery from 
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ethanol precipitation, based on BCA protein concentration assay (see section 2.2.4).  TCA 
precipitation also showed superior removal of SDT, potassium ferricyanide, and sodium 
phosphate, based on visual observations of control solutions containing each of these substances 
individually and subjected to each precipitation protocol.  TCA precipitation showed the best 
performance among all protein clean-up methods tested, which also included dialysis (7kDa 
molecular-weight cutoff), zeba size-exclusion desalting cartridges (7kDa molecular-weight 
cutoff), and microcon centrifugal filters (10kDa molecular-weight cutoff).  The microcon filters 
showed nearly equal performance to TCA precipitation but have significantly greater cost.  In 
addition, proteins can clog the filters, especially given the high concentrations that occur during 
the filtration process.  This leads to long centrifugation times and may also adversely affect 
performance in removal of non-protein solution compnents.  After the TCA precipitation 
process, proteins were re-constituted in 50mM ammonium bicarbonate buffer at pH 9 with 4% 
(w/v) CHAPS.  This buffer was chosen over sodium phosphate for its compatibility with mass 
spectrometry, which was the ultimate goal for proteomic analysis of cardiac protein samples 
labeled by this method. 
 As each preparation of 3NY-Ph-b has some variability in the extent of nitration, protein 
concentrations were adjusted to match the 3NY concentration in the previous experiment, while 
the total Ph-b concentration was different.  The stock of 3NY-Ph-b used for this particular 
experiment contained 2.5mg/mL (approximately 25µM) Ph-b with 6.3mol 3NY per mol Ph-b, 
giving a stock 3NY concentration of approximately 160µM.  Control Ph-b was prepared as 
described in section 3.2.2, with an estimated final concentration of 2.5mg/mL, or approximately 
25µM (assumes no losses during preparation steps).  Cardiac proteins were prepared as described 
in section 2.2.2 from heart tissue harvested from yung (5 months old) rats, with a stock protein 
93 
 
concentration of 0.9mg/mL (based on BCA assay, see section 2.2.4) in 50mM ammonium 
bicarbonate buffer with pH 7.4 and 4% (w/v) CHAPS.  Five solutions of 3NY-Ph-b with a range 
of 3NY concentrations were prepared by serial dilution.  To each of these solutions, control Ph-b 
and cardiac proteins were added to give a total Ph-b concentration of 0.08mg/mL, cardiac protein 
concentration of 0.45mg/mL, and 3NY concentrations (on Ph-b) in the range 0-5.1µM.  SDT, 
prepared immediately before use as described above, was added to each solution to a final 
concentration of 10mM, and the reduction reaction was stopped after 1.5min by TCA 
precipitation, as described above.  After re-constitution in 50mM ammonium bicarbonate, pH 9, 
with 4% (w/v) CHAPS, which required about 30min to complete, samples were derivatized with 
1mM potassium ferricyanide and 5% (v/v; approximately 460mM) benzylamine for 1h at room 
temperature in the dark.  Due to a pipetting error, the potassium ferricyanide concentrations in 
one of the duplicate sample sets was actually 1.8mM, and a slight dilution of other components 
resulted from the small increase in solution volume.  The second set was prepared accurately as 
planned.  Fluorescence spectra were obtained as described in section 3.2.3. 
 Finally, in order to more closely mimic physiological conditions, a lower 3NY 
concentration range was tested.  As another optimization effort, 4% (w/v) CHAPS was replaced 
with 1% (w/v) SDS in both the cardiac and derivatiztion buffers due to its superior performance 
in solubilizing proteins.  In order to avoid ion-pairing and consequent precipitation, pH was 
maintained at 9 during derivatization and all subsequent analysis.  This experiment was 
conducted in triplicate for purposes of statistical analysis and construction of a calibration curve 
against which to measure endogenous 3NY levels in cardiac protein samples.  3NY-Ph-b stock 
was the same as in the previous experiment (2.5mg/mL protein, 160µM 3NY) and was diluted to 
a protein concentration of 0.5mg/mL and 3NY concentration approximately 32µM.  Cardiac 
94 
 
proteins from a young (five months old) rat were prpared as described in section 2.2.2, with re-
constitution in 50mM ammonium bicarbonate buffer, pH 7.4, with 1% (w/v) SDS.  The stock 
protein concentration was 10.2mg/mL, as measured by BCA assay (see section 2.2.4), and this 
was diluted to 0.9mg/mL.  The protocol was the same s the previous experiment, with the 
following changes in concentrations: total Ph-b 0.01 mg/mL and 3NY (in Ph-b) 0-0.64µM.  
Cardiac protein concentration remained 0.45mg/mL, and SDT, potassium ferricyanide, and 
benzylamine concentrations also remained the same as above.  Following the reduction reaction 
and TCA precipitation procedure, re-constitution in the derivatization buffer was aided by 
sonication with three pulses of 10s each at 15% power utput, with 10s breaks between pulses.  
After 1h reaction time at room temperature in the dark, fluorescence spectra were measured as 
described above, and maximal emission intensity near th  expected wavelength (440-460nm) 
was plotted against 3NY concentration.  The mean of triplicate sample sets was used to generate 
a calibration curve and calculate a limit of detection (LOD).  In order to account for larger 
standard deviations in non-blank samples than in the blanks, the LOD was calculated using a 
pooled standard deviation (13).  In addition, samples containing cardiac proteins and control Ph-
b (but no 3NY-Ph-b) were compared to samples containi g only cardiac proteins that did not 
undergo reduction by SDT, using a two-tailed Student’s t-test (13) to determine whether the 
difference between these means was statistically significant. 
3.2.5  Size-Exclusion HPLC (SE-HPLC) 
 SE-HPLC was performed on a Shimadzu 10A Series High-Performance Liquid 
Chromatograph (Kyoto, Japan).  An isocratic method using 0.1M sodium phosphate plus 0.1M 
sodium sulfate, pH 6.8, as a mobile phase at a flow rate of 1.0mL/min separated protein solutions 
on a Tosoh TSK-GEL G3000SWXL column, 7.8mm ID x 30cm, 5µm particles.  The loop v lume 
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for the manual injector was 20µL, and 40µL protein solution was loaded in order to ensure 
complete loop filling.  Detection was by UV absorbance at 280nm and fluorescence at excitation 
360nm and emission 460nm. 
3.2.6  Western Blots for Nitrotyrosine 
 SDS polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting for 
3NY were performed using the Bio-Rad Mini-PROTEAN® electrophoresis and blotting system 
(Hercules, CA, USA).  Samples were prepared with combinations of 3NY-Ph-b carrying 
approximately 5.5mol 3NY per mol protein and cardiac proteins [see section 2.2.2 for 
preparation conditions; buffer was 50mM ammonium bicarbonate at pH 7.4 with 1% (w/v) 
SDS], with or without treatment with 20mM SDT.  After adding SDT (or 18MΩ water for 
controls), samples were mixed with an equal volume of 2X Laemmli sample buffer and heated in 
a boiling water bath for 2min.  For reducing conditions, 5% (v/v) 2-mercaptoethanol was first 
added to the stock solution of sample buffer.  For non-reducing conditions, the sample buffer 
was used as received.  Samples and molecular-weight markers were loaded into pre-cast 4-20% 
gradient gels and separated by electrophoresis in 1X tris/glycine/SDS run buffer at constant 
200V for 38min, with maximum current limited at 400mA. 
 Following SDS-PAGE, protein bands were transferred f om the gels to PVDF 
membranes in 1X tris/glycine buffer (25mM tris(hydroxymethyl)aminomethane, 192mM 
glycine, pH 8.3) with 20% methanol at constant 100V for 2h, with cooling; maximum current 
was limited at 400mA.  Membranes were blocked for 1h with two changes of the blocking 
buffer, which consisted of 5% (w/v) nonfat dried milk, 20mM tris(hydroxymethyl)aminomethane 
hydrochloride plus 150mM sodium chloride, pH 7.4, and 0.1% (v/v) Tween 20.  Incubation for 
2h with anti-3NY primary antibody in blocking buffer at a volume ratio of 1:3,000 was followed 
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by thorough washing with blocking buffer and incubation for 1h with goat anti-mouse HRP 
secondary antibody in blocking buffer at a volume ratio of 1:10,000.  After thorough washing 
first with blocking buffer and then with 20mM tris(hydroxymethyl)aminomethane hydrochloride 
plus 150mM sodium chloride, pH 7.4, with 0.1% (v/v) Tween 20, bands were visualized using 
the ECL Plus kit according to manufacturer’s instruc ions, with reagents A and B in a 40:1 ratio 
and film exposition for 10min.  Membranes were also stained with 0.5% (w/v) Ponceau S in 5% 
(v/v) acetic acid to visualize total protein and evaluate loading and transfer consistency. 
3.2.7  Mass Spectrometry for Identification of Ph-b Modifications After Mixing with 
Cardiac Proteins 
 Protein bands of ca. 100kDa, corresponding to the location of pure Ph-b, were excised 
from the SDS-PAGE gel (prepared as described in section 3.2.6), washed extensively and 
digested in-gel with trypsin to extract peptides for HPLC-MS/MS analysis.  Samples were 
separated by capillary HPLC (capLC) with on-line elctrospray ionization (ESI) into an LTQ-FT 
hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance (FTICR) mass 
spectrometer (ThermoFinnigan, Bremen, Germany).  Sample handling and data analysis methods 
were analogous to a published procedure (3). 
3.3  Results 
3.3.1  Protein Derivatization 
 Under the conditions described in section 3.2.3, the labeling reaction appears to proceed 
rather quickly, reaching 62% of the final fluorescen  intensity after only 8min reaction time and 
84% after 25min (Fig. 3.1).  After approximately 1h total reaction time, the fluorescence 
intensity for the tagged Ph-b sample is substantially l rger than any background fluorescence in 
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the control samples (Fig. 3.2).  It is also 
noteworthy that the wavelengths of maximum 
intensity shift for controls omitting either 
potassium ferricyanide or benzylamine.  
3.3.2  Derivatization Results in Presence of 
Cardiac Proteins 
3.3.2.1  Linear Dependence of Fluorescence 
Intensity on Concentration of 3NY-Ph-b 
Samples of 3NY-Ph-b that were first 
derivatized with benzylamine and then mixed 
with cardiac protein solutions showed a linear respon e in fluorescence emission intensity with 
relation to 3NY concentration (Fig. 3.3).  The data is corrected by subtracting the baseline 
fluorescence of a control 
containing only cardiac 
proteins and buffer.  The 
SE-HPLC results for 
these same samples show 
a correlation that is not as 
linear as the fluorescence 
intensity data.  Fig. 3.4 
shows plots of both 
fluorescence and UV peak 
areas, also corrected by 
Fig. 3.1  Time course for derivatization of 
nitrated Ph-b with benzylamine. 
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subtracting the values for the cardiac protein-only 
control, against the 3NY concentration.  These 
results are based on a single experiment, and the 
fluorescence chromatograms were of fairly low 
intensity. 
 When 3NY-Ph-b, control Ph-b, and 
cardiac proteins were mixed prior to reduction 
and tagging, a clear linear relationship 
was observed between the maximal 
fluorescence intensity near the expected 
emission wavelength (440-460nm) and the 
concentration of 3NY in Ph-b.  Fig. 3.5 
shows data for each of the duplicate 
sample sets, as well as their mean values, 
all of which have R2 > 0.99.  The variation 
between the two sample sets may be due 
to the pipetting error described in section 
3.2.4, but the mean nevertheless shows 
good linearity.  The data have been 
corrected by subtraction of fluorescence 
from the sample containing no 3NY-Ph-b.  
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Due to the differing experimental conditions 
introduced by the pipetting error, this 
calibration curve was not used for any 
calculations.  Instead, a new experiment was 
designed with several methodological 
improvements, as described in section 3.2.4. 
 When 3NY concentrations were 
decreased in order to test the LOD and come 
closer to physiological levels, a linear 
relationship was once again observed between 
corrected fluorescence intensity and 3NY 
concentration (Fig. 3.6).  Combining data from the higher (i.e., Fig. 3.5 and lower (i.e., Fig. 3.6) 
3NY concentration regimes reveals the 
linearity of this relationship over the entire 
range tested (Fig. 3.7).  Only sample set 2 was 
used for the higher concentration regime in 
this plot because of the inadvertent increase in 
potassium ferricyanide concentrations for 
sample set 1, which can significantly impact 
fluorescence intensity.  The data for higher 
3NY concentrations is thus limited to n=1.  
Averages and standard deviations were taken 
for all points available at a given 
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Fig. 3.5  Linear dependence of fluorescence 
on 3NY concentration in Ph-b mixed with 
cardiac homogenate solution and derivatized 
with benzylamine, in duplicate. 
Fig. 3.6  Linear dependence of fluorescence 
on 3NY concentration (0-0.64µM) in Ph-b 
mixed with cardiac homogenate solution and 
derivatized with benzylamine, in triplicate. 
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concentration: n=4 for 0, 0.64; n=3 for 0.08, 0.16, 0.32; n=1 (no average or standard deviation) 
for 1.28, 2.56, 5.12.  It should also be noted thatsome experimental parameters were changed 
between these two experiments, most notably the use of CHAPS in the higher-concentration 
experiment and SDS in the lower-concentration experiment.  Nevertheless, the consistency of the 
data between these two experiments provides evidence for the linear response of this method 
over a concentration range spanning a 64-fold difference between the highest and lowest values 
(0.08-5.12µM).  
3.3.2.2  Limit of Detection 
 The experiment using lower 3NY concentrations was performed in triplicate, and 
statistical analysis determined the LOD to be 608nM 3NY, according to the equation 
	  
  3 
Eq. 3.2 
where yLOD is the fluorescence intensity at the limit of detection, yblank is the fluorescence 
intensity of the control sample (containing cardiac protein and control Ph-b, but lacking 3NY-Ph-
b), and spooled is the pooled standard deviation of all samples.  This method was selected in order 
to account for larger standard deviations for the non-blank samples than for the blank (13).  In 
order to calculate the 3NY concentration that corresponds to yLOD, the linear regression equation 
of the calibration curve was solved for xLOD: 
	  105	  300 
Eq. 3.3 
Note that this equation was derived from a plot of uncorrected fluorescence intensities as a 
function of 3NY concentration (not shown, as the corrected data was selected for presentation).  
The uncorrected data was used for LOD calculation in order to include deviation values for the 
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blank sample in the calculation of spooled.  For the sake of comparison, calculation of the LOD by 
a simpler method, according to the equation 
	  
  3
 
Eq. 3.4 
where sblank is the standard deviation for the blank sample and the other terms are as defined 
above, gives a value of 8nM 3NY.  However, this fails to account for the much greater variability 
in measurements for samples that contain 3NY-Ph-b. 
3.3.2.3  Calibration for Endogenous 
Cardiac Modifications 
 Comparison of a sample containing 
only cardiac protein that was not reduced by 
SDT to a sample containing cardiac protein 
and control Ph-b that was reduced by SDT 
was planned as a method to measure the 
amount of endogenous 3NY present in the 
cardiac protein.  The non-reduced sample, 
having been exposed to all aspects of the 
derivatization protocol other than addition of 
SDT, should not contain any labeled 3NY, 
although some background fluorescence is 
expected, including from the benzylamine-
dependent derivatization of any endogenous DOPA or 5-hydroxytryptophan it may contain.  On 
the other hand, the reduced sample would contain labeled 3NY as well as any DOPA or other 
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Fig. 3.7  Linear dependence of fluorescence 
on 3NY concentration in Ph-b mixed with 
cardiac homogenate solution and derivatized 
with benzylamine.  Data combined from 
multiple experiments to show the entire 3NY 
concentration range tested: n=4 for 0µM, 
0.64µM; n=3 for 0.08µM, 0.16µM, 0.32µM; 
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background fluorescence present in the non-reduced sample.  Contrary to expectations, the non-
reduced sample had greater fluorescence intensity than the reduced sample.  However, by a two-
tailed Student’s t test using a pooled standard deviation (13), it was shown that the difference in 
mean fluorescence intensities for these two samples was not statistically significant.  Therefore, 
it can be concluded that endogenous 3NY in these cardiac samples is below the LOD = 608nM.  
Using an approximate average molecular weight of 50kDa to estimate the moles of protein in the 
sample, an estimate of an average 420 amino acid resi ues per protein (50kDa protein, average 
molecular weight of the 20 amino acids is 119Da – not weighted for frequency of each amino 
acid), and the natural abundance of Tyr, which is 3.4%, it was calculated that the LOD of 608nM 
3NY translates to nitration of approximately 0.48% of all Tyr residues in the cardiac protein 
sample.  Since 3NY levels around 0.01-0.05% have been observed under inflammatory 
conditions (8), it is not surprising that 3NY levels in cardiac proteins from young rats are below 
this LOD. 
3.3.3  Observed Loss of 3NY in Ph-b upon Mixing with Cardiac Proteins 
3.3.3.1  Detection of Nitrotyrosine Epitope by Western Blotting Diminishes with Addition 
of Cardiac Proteins  
 In Fig. 3.8, 3NY-Ph-b was exposed to varying levels of cardiac homogenate, with or 
without reduction by SDT, which is known to remove th 3NY epitope by converting it to 3AY.  
Non-reducing conditions were employed in order to av id any possible artifactual reduction of 
3NY to 3AY, for example by DTT or 2-mercaptoethanol and heme.  The results of two similar 
experiments are shown to demonstrate reproducibility and to provide clear visualization of all 
sample types, as some variation in the blot results are typical for this technique.  There is an 
obvious reduction in size of the immunoreactive 3NY-Ph-b band when it is mixed with 
103 
 
increasing amounts of cardiac homogenate (Fig. 3.8a, . b, 3.8d), even though total protein 
staining with Ponceau S shows the persistence of a band near 100kDa, corresponding to Ph-b 
(Fig. 3.8e).  In addition, SDT eliminates immunoblot bands for 3NY-Ph-b in each case.  Some 
cardiac proteins above 50kDa show some sensitivity o reduction by SDT, but other bands, 
especially those near 25kDa and 50kDa, show little or no change upon SDT treatment (Fig. 3.8a, 
3.8b).  The SDT-insensitive bands likely indicate artif ctual detection, and these proteins 
probably do not contain 3NY.  Non-specific binding of the secondary antibody may be to blame, 
since these bands are absent in experiments that omit he primary antibody or switch to a rabbit 
polyclonal primary antibody with an anti-rabbit secondary antibody (Elena Dremina, 
unpublished results).   
Fig. 3.9 illustrates the effect of SDT reduction on both 3NY-Ph-b and cardiac proteins, 
using SDS-PAGE with reducing conditions.  There are fewer bands for cardiac proteins than in 
Fig. 3.8, most likely due to the breakage of sulfide bonds by the reducing conditions of the 
sample buffer.  In parts a and b of Fig. 3.9, lane 8 should contain 50µg of cardiac protein but 
appears to be empty (by Ponceau staining, Fig. 3.9b), indicating sample loss somewhere in the 
procedure.  Nevertheless, all of the other results provide evidence for the loss of 3NY in Ph-b 
with SDT treatment, while it has no effect on the few bands observed in the cardiac homogenate. 
3.3.3.2  Mass Spectrometric Characterization of Ph-b after Mixing with Cardiac Proteins 
 For this portion of the project, it seemed prudent to collaborate with Elena Dremina to 
utilize her experience in preparing gel-based samples for mass spectrometric detection of 
protein-bound 3NY.  Samples of 3NY-Ph-b (5.5mol 3NY per mol Ph-b) and cardiac proteins, 
prepared as described in sections 3.2.2 and 2.2.2, respectively, along with conditions used for the 
SDS-PAGE and Western blot experiments illustrated in Figure 3.8, were supplied to her.  After 
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replicating the SDS-PAGE experiment, she extracted tryptic peptides from the Ph-b protein 
bands and submitted them for HPLC-MS/MS analysis, a described in section 3.2.7.  The results 
  
Fig. 3.8 Western blots for 3NY showing the effect 
of cardiac homogenate solutions and SDT 
reduction on 3NY epitopes in Ph-b nitrated in 
vitro.  SDS-PAGE was performed with non-
reducing conditions.  Blots and Ponceau-stained 
membranes are shown from two similar 
experiments, with sample contents as shown.  For 
the first experiment, the film was exposed for 10s 
(a) or overnight (b), followed by Ponceau 
staining for total protein (c).  For the second 
experiment, the film was exposed for 10min (d) 
followed by Ponceau staining for total protein (e). 
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of this analysis show a reduction of mass spectral ounts for tryptic peptides of Ph-b containing 
3NY (Tyr+45amu) upon addition of increasing amounts of cardiac homogenate (Table 3.1).  
While a small reduction is also seen in mass spectral ounts for unmodified peptides, it is not as 
great as for 3NY-containing peptides (Table 3.1).  [As this data represents a single experiment, 
additional replicates are currently in preparation in order to assess the reproducibility of this 
result and to perform statistical analysis.] 
Fig. 3.9  Western blots showing the effect of SDT reduction on 3NY epitopes in both Ph-b nitrated 
in vitro and in cardiac homogenate solutions.  SDS-PAGE was performed with reducing 
conditions.  Blots and Ponceau-stained membranes are shown from two similar experimnts, with 
sample contents as shown.  For the first experiment, the film was exposed overnight (a), followed 
by Ponceau staining for total protein (b).  For the second experiment, the film was exposed for 
10min (c) followed by Ponceau staining for total protein (d). 
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 In addition, some tryptic peptides containing 3NY were observed to have decreased 
HPLC-MS peak areas, based on integration in Excalibur software, in the presence of cardiac 
protein (Table 3.2).  For some of these tryptic peptides, the decrease in peak area for the 3NY-
containing peptide was accompanied by an increase in p ak area for its native Tyr-containing 
counterpart (Table 3.2). 
 No peptides containing 3AY were detected in the HPLC-MS/MS search data.  Searches 
with P-Mod software did not find any recognizable Tyr modifications other than 3NY 
(Tyr+45amu).  Thus, the data support the hypothesis that 3NY is converted back to native Tyr 
when incubated with cardiac homogenate. 
Amount 
3NY-Ph-b (µg) 
Amount 
cardiac protein 
(µg) 
Ph-b sequence 
coverage 
Total spectrum 
count for 
Tyr+45amu 
Total spectrum 
count for 
unmodified 
peptides 
0.5 0 64% 42 
≡100% 
81 
≡100% 
0.5 10 63% 37 
88% 
83 
102% 
0.5 50 65% 27 
64% 
67 
83% 
1.0 0 63% 61 
≡100% 
105 
≡100% 
1.0 10 66% 58 
95% 
104 
99% 
1.0 50 64% 39 
64% 
81 
77% 
 
Table 3.1  Summary of mass spectrometry results for 3NY-Ph-b in the absence or presence of 
cardiac proteins.  Sequence coverages and spectral counts represent identified tryptic peptides 
of Ph-b only.  For comparison of spectral counts, the value obtained in the absence of cardiac 
protein is defined as 100% and used as a reference point for values obtained in the presence of 
cardiac proteins under conditions that are otherwise the same. 
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Table 3.2  HPLC-MS peak areas for selected tryptic peptides of Ph-b, in samples containing 0.5µg 
3NY-PhB.  [Y+45] indicates 3NY identification.  Peptide sequences include in parentheses the 
identities of residues adjacent to the tryptic cleavage sites. 
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3.4  Discussion and Conclusions 
Conditions for derivatization of 3NY-Ph-b with benzylamine were successfully 
optimized, and these conditions also performed wellhen this nitrated protein was diluted in a 
matrix of cardiac homogenate.  Fluorescence spectrometry showed a showed a linear response of 
intensity to 3NY concentration in Ph-b, and this data enabled calculation of the limit of 
detection, 608nM 3NY.  Parallel experiments with cardi c proteins, in the absence of 3NY-Ph-b, 
demonstrated that the difference in mean fluorescence intensity between non-SDT-reduced 
samples (3NY cannot be labeled) and SDT-reduced samples (3NY should be labeled) was not 
statistically significant.  Thus, the amount of endogenous 3NY modifications in cardiac samples 
is assumed to be below the detection limit, which is consistent with nitration levels previously 
reported in the literature (8).  For this reason, future work would benefit from nitration of cardiac 
proteins in vitro, such as by peroxynitrite, to test whether the method is capable of labeling 
nitrated cardiac proteins when they are present at higher concentrations.  By diluting the in-vitro-
nitrated cardiac proteins with untreated cardiac proteins, a limit of detection could also be 
determined for this type of sample, which would contain a variety of labeled proteins instead of a 
single protein analyte.  discuss how low nitration levels can have significant biological impact 
(8). 
Other model systems, such as tissues exposed to inflammatory insult, may also have 
higher endogenous levels of 3NY that could be more easily detected by this method.  Protein 
oxidation products can also be concentrated in certain cellular compartments, such as 
mitochondria (8,15), and in certain tissues (8), such as the cataractous lens (4).  It is possible to 
isolate some of these compartments, which could provide a more robust sample to which this 
technique can be applied.  In addition, a similar method using 4-(aminomethyl)benzenesulfonic 
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acid (ABS) has been successfully applied to detect oxidative Tyr modifications in recombinant 
proteins exposed to oxidizing conditions (14,16). 
Western blot and mass spectrometric analysis provide evidence for the removal of 3NY 
from 3NY-Ph-b when it is incubated with cardiac homogenate.  Some of the mass spectrometry 
data suggest that 3NY is converted to native Tyr, but further experimentation is necessary to 
confirm this hypothesis.  If the cardiac homogenate is capable of denitrating proteins, this may 
also explain the difficulties in detecting and identifying endogenous protein-bound 3NY in 
cardiac proteins.  Under the conditions employed for preparing cardiac homogenate samples, it is 
not expected that enzymes would survive in their act ve forms.  Specifically, reductive 
alkylation, cold ethanol precipitation, and the addition of detergent (SDS or CHAPS) create 
denaturing conditions.  Thus, a non-enzymatic de-nitration mechanism seems more likely.  
Protease inhibitors are included in the initial lysis conditions, so proteolytic degradation is not 
expected to make a major contribution.  In support of this assumption, Ponceau staining for total 
protein on immunoblot membranes shows the persistence of a band at the migration position of 
Ph-b in the presence of cardiac proteins (Fig. 3.8).  In addition, mass spectrometric data shows 
similar sequence coverage and spectral counts for Ph-b in the absence or presence of cardiac 
proteins (Table 3.1). 
Analysis of MS/MS data for Tyr modifications indicates that increasing amounts of 
cardiac protein leads to a decrease in 3NY levels, ba ed on spectral counts (Table 3.1) and 
HPLC-MS peak areas (Table 3.2), and an increase in nat ve Tyr levels for the same tryptic 
fragment sequences (Table 3.2).  This is consistent with literature reports of conversion of 3NY 
to native Tyr in matrices that promote denitration (1).
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Chapter 4:  Effect of Amino Acid Sequence on Fluorescence Quantum Yield, 
Molar Absorptivity, and Reaction Yield for a Series of Model Synthetic 
Nitropeptides Labeled with 
(3R,4S)-1-(4-(aminomethyl)phenylsulfonyl)pyrrolidine-3,4-diol (APPD) 
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4.1 Introduction 
4.1.1 Peptide Sequences and Properties 
 Based on a tryptic fragment of the rat muscle protein glycogen phosphorylase b (Ph-b) 
with a known nitration site when treated in vitro with peroxynitrite (19), the synthetic 
nitropeptide FSA(3NY)LER became an important model for development of this novel 
derivatization method.  (The nitration site was identified from the rabbit homolog protein, in 
which the tryptic fragment sequence is FAAYLER.)  Since proteomic samples contain an 
expansive variety of peptide sequences, each with different physical and chemical properties, we 
were interested to study what effects these properties may have on tagging efficiency and 
product characteristics.  Toward this end, a series of synthetic nitropeptides was tested with the 
derivatization protocol optimized for FSA(3NY)LER.  Replacement of leucine with glutamate to 
give FSA(3NY)EER or arginine to give FSA(3NY)RER alters the acidity and charge state of the 
peptide.  The addition of a second 3NY, again in place of leucine to give FSA(3NY)(3NY)ER, 
enables the study of two adjacent candidates for derivatization.  Some evidence for the 
derivatization of adjacent nitrotyrosine residues was observed in cardiac proteomic samples (see 
section 2.3.13).  Finally, a tryptic fragment of nitrated calmodulin with the sequence 
VFDKDGNG(3NY)ISAAELR was previously observed (12) to give a Lys-Tyr crosslink upon 
derivatization by our method (see Fig. 4.1c for structure), and so this sequence was selected as 
the fifth model peptide in the series.  
4.1.2 Derivatization Products 
 (3R,4S)-1-(4-(aminomethyl)phenylsulfonyl)pyrrolidine-3,4-diol (APPD) was selected for 
this project due to its ability to label 3NY with both an affinity moiety and a fluorophore, which 
makes it a promising candidate for proteomic studies of endogenous modifications with low 
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abundance.  Previous work with model compounds, including small molecules, peptides, and 
proteins, indicates three possible product structures (Fig. 4.1).  These include the addition of two 
molecules of APPD per Tyr residue (a), the addition of APPD and ammonia (b), and the addition 
of APPD with an intramolecular crosslink, which can involve either a Lys residue (c) or the N-
terminus (d). 
4.1.3 Fluorescence Quantum Yield 
 The fluorescence quantum yield, Φ of a compound is defined as the number of photons 
emitted as fluorescence per photon absorbed, with a maximum value of 1.0 (3).  Multiple 
processes compete with fluorescence during relaxation from the excited state back to the ground 
state, including internal conversion, radiationless relaxation, intersystem crossing, and 
phosphorescence.  Thus, the fluorescence quantum yield is an important measure of the 
efficiency of fluorescence for a particular molecule, relative to other processes.  It is also a useful 
indicator of the sensitivity of assays that are based on particular fluorogenic labels (20). 
 The relative fluorescence quantum yield of a compound can be determined by 
comparison to a reference compound with a known fluorescence quantum yield, according to the 
equation (11,14,20): 
  	 
      	


      	


 
Eq. 4.1 
where the subscript R denotes the reference compound, Φ is the fluorescence quantum yield, F is 
the peak area of the fluorescence emission spectrum, q is the relative photon output of the source, 
A is the absorbance at the excitation wavelength, and n is the refractive index of the solvent.  
When the same instruments, excitation wavelengths, and solvents are used for both the reference 
compound and the new compound, the q and n terms cancel and can be omitted from the 
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calculation.  If different instruments are used for measuring absorbance and fluorescence, as is 
often the case, care should be taken to use the samb ndwidth or slit width for the incident light 
in both measurements, i.e. the bandwidth in the UV-visible spectrophotometer should match the 
excitation bandwidth in the spectroflourophotometer.  Moreover, the sample should be purified 
to contain only the fluorescent molecule of interest in order to avoid interference, particularly in 
the absorbance measurement.  This method was previously used by Sharov et al. (17) to 
determine the fluorescence quantum yield of the peptid  FSA(3NY)LER labeled with 4-
(aminomethyl)benzenesulfonic acid, a reagent which is very similar to APPD. 
4.1.4 Absolute Peptide Quantitation 
 In order to determine both the chemical reaction yields and the molar absorptivities (i.e. 
extinction coefficients) of the various labeled peptide products, it is necessary to measure 
absolute quantities of these products.  Amino acid nalysis is particularly well-suited to this task 
(2,4).  Using external calibration standards of amino acid mixtures, along with an internal 
standard, a calibration curve can be constructed using normalized peak areas for a selected amino 
acid, such as alanine, and then used for absolute quantitation of the alanine-containing peptide 
product, which has been purified from other alanine-containing substances (2,15). 
 Vapor-phase hydrolysis by hydrochloric acid is performed at high temperature under 
vacuum to release individual amino acids from the peptides (7).  Complete hydrolysis of the 
peptide to its constituent amino acids, or at least a consistent and known extent of hydrolysis, is 
important for accurate quantitation.  Some amino acids, such as Cys, Ser, Thr, Gln, Asn, Tyr, and 
Trp, are not stable under these hydrolysis conditions and thus cannot be used for accurate 
quantitation without specific modifications to the method. 
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 Following hydrolysis, amino acids must be derivatized to enable detection by either UV 
absorption or fluorescence during high-performance liquid chromatography (HPLC), usually 
with a reverse-phase or ion-exchange column.  A variety of methods exist, involving both pre- 
and post-column derivatization.  In this work, o-phthaldialdehyde (OPA) reacts with primary 
amines in the presence of thiols to give fluorescent products that can be detected in low picomole 
amounts (5,18).  Secondary amines, such as proline, are not detected by this method.  Due to 
limited product stability, this reaction must be performed immediately prior to HPLC analysis of 
each sample (18). 
 Based on this absolute quantitation of nitropeptide, reduced peptide (i.e. aminopeptide), 
and labeled peptide, the yield of each reaction step can be calculated.  In addition, the 
concentration of each solution used for spectroscopy is known.  Beer’s law gives the relationship 
   
Eq. 4.2 
where A is absorbance, ε is molar absorptivity (i.e. extinction coefficient), b is the path length, 
and c is the concentration of the absorbing species.  Thus, for a known analyte concentration, the 
measured absorbance can be used to determine the molar absorptivity of the analyte at the 
selected wavelength.  This will allow for comparison  among different peptide sequences with 
regard to reaction efficiency and photochemical prope ties. 
4.2 Experimental Methods 
 A flow chart of the overall methodological approach for characterizing this series of 
model peptides throughout the derivatization process with APPD is shown in Fig. 4.2.  
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Fig. 4.2 Method flow chart for characterization of model peptides labeled with APPD.  3NY, 
3-nitrotyrosine; AAA, amino acid analysis; HPLC-MS/MS, high-performance liquid chromatography 
with tandem mass spectrometry; RP-HPLC-UV, reverse-phase high-performance liquid chromatography 
with UV-visible absorbance detection; 3AY, 3-aminotyrosine; APPD, (3R,4S)-1-(4-
(aminomethyl)phenylsulfonyl)pyrrolidine-3,4-diol; RP-HPLC-UV-FL, reverse-phase high-performance 
liquid chromatography with UV-visible absorbance and fluorescence detection. 
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4.2.1 Materials 
 Synthetic nitropeptides were prepared and purified to >95%, as determined by HPLC, by 
the Biochemical Research Service Laboratory at the University of Kansas using Fmoc-protected 
amino acids, including Fmoc-3NY (Bachem Bioscience, King of Prussia, PA, USA).  Additional 
stock of the custom peptide FSA(3NY)LER was purchased from EZBiolab, Carmel, IN, USA. 
 Glutathione in its reduced form, minimum purity 98%; ammonium bicarbonate; o-
phthalaldehyde (OPA); 2-mercaptoethanol; sodium acetate; L-norvaline; sodium dithionite 
(SDT), synonym sodium hydrosulfite, technical grade, 85%; potassium ferricyanide; 
trifluoroacetic acid (TFA), ≥99%, purified by redistillation, for protein sequencing; acetonitrile; 
methanol; and tetrahydrofuran were all purchased from Sigma-Aldrich (St. Louis, MO, USA).  
All mobile phase solvents were HPLC or MS grade.  For reverse-phase HPLC (RP-HPLC), all 
mobile phases were filtered with 0.45µm Nylon-66 filters (Sigma-Aldrich, St. Louis, MO, USA). 
ThioGlo®1 Fluorescent Thiol Reagent was from Calbiochem/EMD Millipore (Billerica, 
MA, USA) and was dissolved in acetonitrile to give a 2mM stock solution, which was stored at -
20°C. 
 Constant-boiling, sequanal grade, 6N hydrochloric acid for vapor-phase hydrolysis of 
peptides was obtained from Thermo Scientific (Rockfrd, IL, USA), as was Amino Acid 
Standard H. 
Monobasic potassium phosphate, enzyme grade; and 12N hydrochloric acid, Certified 
ACS Plus, were from Fisher Scientific (Pittsburgh, PA, USA). 
Ethanol, 100% (meets USP specifications), was from Decon Laboratories, Inc., King of 
Prussia, PA, USA. 
APPD was synthesized in-house according to a previously published method (9). 
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4.2.2 Peptide Derivatization and Product Isolation 
 Stock solutions of each peptide were prepared in 18MΩ water and concentrations 
determined by 3NY absorbance measurements on a Cary 50 Bio UV-Visible Spectrophotometer, 
using the extinction coefficient ε356nm = 2,910M
-1cm-1 in 0.01N hydrochloric acid (10).  When 
not limited by solubility, the stock concentration was adjusted to 1.0mM.  This method was 
found to be much more accurate than gravimetric analysis. 
All RP-HPLC analysis was conducted with a Shimadzu 20A Series Prominence High-
Performance Liquid Chromatograph (Kyoto, Japan), with all injections made by the autosampler.  
For the calmodulin peptide, RP-HPLC analysis of the nitropeptide solution revealed possible 
peptide degradation and/or impurity.  For this reason, the nitropeptide was first isolated by RP-
HPLC, using the gradient and method described below for post-reduction isolation.  Multiple 
aliquots were pooled and dried to produce a stock of purified calmodulin nitropeptide, the 
concentration of which was determined by absorbance t 356nm, as described above, and the 
stock concentration was adjusted to 1.0mM. 
 For reduction of 3NY to 3AY, 5mM sodium dithionite (SDT) was added to 500µM 
peptide in 120µL total volume.  SDT solutions were always prepared fresh by dissolving the 
solid in the appropriate amount of 18MΩ water immediately prior to use, in order to avoid 
decomposition that can occur within minutes of dissolution.  After a reaction time of one minute, 
100µL of the reduced peptide solution was injected onto RP-HPLC for purification, using an 
octadecyl stationary phase (Vydac 218TP C18, 4.6mm x 250mm, 5µm particle size, 300Å pore 
size; Fisher Scientific, Pittsburgh, PA, USA) and a linear gradient from 5-29% acetonitrile in 
water with 0.1% trifluoroacetic acid (TFA) over 24min at a flow rate of 1.0mL/min.  Any 
remaining compounds were removed with a steep gradient from 29% to 80% acetonitrile plus 
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0.1% TFA over 1min and a 10min wash with this solvent, followed by 15min re-equilibration 
with starting conditions.  Detection was performed with a photodiode array (PDA) UV-visible 
detector, monitored at 214nm for collection of the fraction containing the aminopeptide product 
(in a borosilicate glass tube), as verified by mass spectrometry (MS).  This product was dried 
completely using a Centrivap Concentrator (Labconco, Kansas City, MO, USA) and re-
constituted in 250µL 18MΩ water. 
 Derivatization was carried out in 50mM ammonium bicarbonate buffer at pH 9, using 
500µM potassium ferricyanide and 20mM APPD to label approximately 50µM aminopeptide in 
a total volume of 120µL.  The exact peptide concentration was dependent on the yield from the 
reduction step, which was determined later by amino acid analysis (see Sections 4.2.5 and 4.3.5).  
After 10min reaction time in the dark at room temperature, 100µL was injected onto RP-HPLC 
to isolate the major fluorescent product.  A two-part linear gradient of acetonitrile in water with 
0.1% TFA eluted the products from the octadecyl station ry phase: 5-20% over 10min, then 20-
41% over 21min, with a constant flow rate of 1.0mL/in.  Any remaining compounds were 
removed with a steep gradient from 41% to 80% acetonitrile plus 0.1% TFA over 1min and a 
10min wash with this solvent, followed by 15min re-equilibration with starting conditions.  
Detection was primarily by fluorescence with 370nm and 510nm as the excitation and emission 
wavelengths, respectively.  Chromatograms were also rec rded with a (PDA) UV-visible 
detector.  The fraction containing the major fluoresc nt product was collected in quartz tubes to 
avoid possible interactions between the cis-diol affinity moiety and boronate groups that may be 
accessible in borosilicate glass.  These fractions were evaporated to dryness in a Centrivap and 
re-constituted in an appropriate amount of 18MΩ water for further analysis by fluorescence and 
UV-visible spectroscopy, MS, amino acid analysis, and HPLC.  In some cases, to be noted 
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below, it was necessary to pool products collected from multiple reaction replicates in order to 
achieve concentrations high enough for subsequent analysis. 
4.2.3 Preparation of Reference Compound, Glutathione-ThiGlo®1 (GSH-TG1) 
 The reduced form of the tripeptide glutathione (sequence γ-Glu-Cys-Gly) was labeled at a 
concentration of 100µM by addition of 200µM of the commercial fluorescent thiol labeling 
reagent ThioGlo®1, in a total of 120µL buffered at pH 7 by 20mM sodium phosphate.  After two 
minutes, the fluorescent peptide product was purified rom excess reagent by RP-HPLC, using 
the same conditions described above for APPD-labeled products, except the fluorescence 
detection excitation and emission wavelengths were 379nm and 495nm, respectively.  The 
fluorescent fraction (with retention time ~16-18min) was collected in borosilicate glass, 
evaporated to dryness in a Centrivap, and re-constituted in 600µL 18MΩ water for subsequent 
analysis.  Thiol adducts of ThioGlo®1 have fluorescen e excitation and emission maxima at 
379nm and 495nm, respectively, and the fluorescence quantum yield has been determined as Φ = 
0.49 (6,13,21). 
4.2.4 Mass Spectrometry for Product Identification 
 Peptides from each derivatization step were analyzed by capillary HPLC-MS.  A Vydac 
octadecyl column (25 cm x 0.5 mm, 3.5 µm) was connected to the capillary liquid 
chromatography system (Waters Corporation, Milford, MA, USA).  Mobile phases consisted of 
water/acetonitrile/formic acid at a ratio of 99%, 1%, 0.08% (v:v:v) for solvent A and a ratio of 
1%, 99%, 0.06% (v:v:v) for solvent B.  The following linear gradient was set: 20-80% of solvent 
B over 6 min, with a flow rate of 20µL min-1 and an injection volume of 10µL.  This method was 
optimized for short analysis times because the peptid s had previously been purified by RP-
HPLC (see 4.2.2).  Electrospray ionization (ESI)-MS spectra of the peptides were acquired on a 
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SYNAPT-G2 (Waters Corp., Milford, MA, USA).  The cone voltage was 45V, and Ar was 
admitted to the collision cell.  The spectra were acquired using a mass range of 50-2,000amu.  
The data were accumulated for 0.7s per cycle. 
4.2.5 UV-Visible and Fluorescence Spectroscopy 
 UV-visible spectra were measured with a Cary 50 Bio UV-Visible Spectrophotometer, 
which has a fixed bandwidth of 1.5nm.  Spectra were collected from 500nm to 250nm at a scan 
rate of 300.00nm/min.  Zero and baseline measurements were taken with 18MΩ water as a 
blank, and the software’s baseline correction functio  was enabled.  Using the X-Y Pairs Table 
generated by the software, the absorbance value for wavelength 375nm (A375) was used for 
fluorescence quantum yield calculations according to Eq. 4.1 (see 4.1.3) as the value for A or AR 
for APPD-labeled peptides or GSH-TG1, respectively.  This wavelength was selected as a 
midpoint between the maximum excitation wavelengths previously observed for APPD-labeled 
peptides (370nm) and GSH-TG1 (379nm), since using a single wavelength for both compounds 
is important for accurate quantum yield calculations. 
 The average A375 was determined for at least three replicates of each APPD-labeled 
peptide.  One aliquot of GSH-TG1 was then diluted to match this average absorbance and used 
as the reference compound for the entire peptide sample set.  Samples were prepared such that 
0.01 < A375 < 0.10 in order to avoid reabsorption and internal eflection phenomena that can 
interfere with accurate quantum yield calculations (1,14,20).  When product yields were 
particularly low, this was not always possible. 
 Fluorescence spectra were measured with a Shimadzu RF-5301PC 
Spectrofluorophotometer (Kyoto, Japan) with excitation at 375nm, emission range 385-700nm, 
both excitation and emission slit widths set to 1.5nm, scan speed set to slow, high sensitivity, and 
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automatic response time.  Peak areas were calculated by the software over the entire range of the 
spectrum and used for fluorescence quantum yield calculations according to Eq. 4.1 (see 4.1.3) 
as the value for F or FR for APPD-labeled peptides or GSH-TG1, respectively. 
4.2.6 Amino Acid Analysis for Peptide Quantitation 
 Following spectroscopic measurements, triplicates of each sample were prepared for 
vapor-phase hydrolysis using the Waters Pico.TagTM Workstation (Milford, MA, USA).  
Samples, along with 150pmol of norvaline (Nva) in 0.1N hydrochloric acid as an internal 
standard, were aliquotted into 6mm x 50mm borosilicate glass tubes (Pyrex Vista, Sigma-
Aldrich, St. Louis, MO, USA) that had previously been washed with 8N hydrochloric acid, 
rinsed with 18MΩ water and 100% ethanol, and dried under vacuum.  Samples were then dried 
under vacuum, sealed, and stored at -20°C until analysis.  For APPD-labeled peptides, this was 
always done on the same day that the purified products were re-constituted and used for 
spectroscopic measurements. 
For hydrolysis, 14 sample tubes were placed in the specialized reaction vessel (Eldex, 
Napa, CA, USA) with 200µL 6N hydrochloric acid and subjected to three cycles of evacuation 
and nitrogen purgation for 5s at 2psi.  Hydrolysis was demonstrated to be complete for 
nitropeptide standards of known concentration (measured by UV-Visible spectroscopy, ε356 = 
2910M-1cm-1) after 1.5h at 150°C under vacuum of approximately 1Torr.  The hydrolyzed 
samples were transferred to a clean vial, which was ev cuated to remove all acid fumes, and then 
stored -20°C until ready for HPLC analysis. 
 The reaction of primary amines with OPA in the presence of free thiol (2-
mercaptoethanol) and Brij-35 detergent at pH 9.5 was selected for fluorescent derivatization of 
amino acids (5).  Brij-35 stock solutions were 1% (w/v) in 190mM potassium phosphate pH 9.5 
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buffer, and the OPA reagent stock solution contained 15.7mM OPA, 5.3% methanol, 190mM 
postassium phosphate pH 9.5 buffer, and 0.2% 2-mercaptoethanol.  All reagents and buffers 
were stored at 4°C in the dark when not in use, and the OPA reagent solution was made fresh at 
least every seven days.  Each day, a fresh 1:1 mixture of Brij and OPA stock solutions was 
prepared, and hydrolyzed samples were reacted for 1min with 40µL of this mixture, followed by 
quenching with 80µL 0.2M monobasic potassium phosphate, pH ≤ 4.5.  RP-HPLC was carried 
out on a SUPELCOSILTM LC-18-T octadecyl column, 15cm x 4.6mm with 3µm particle size 
(Sigma-Aldrich, St. Louis, MO, USA) maintained at 35°C by an Alltech 530 column heater 
attached to the Shimadzu system described in section 4.2.2.  Derivatized amino acids were well 
resolved using a flow rate of 0.7mL/min and the gradient shown in Table 4.1, where mobile 
phase A is 95% 25mM sodium acetate, pH 5.8, with 5% THF and mobile phase B is 95% 
methanol with 5% THF, based on a previously published method (22). 
Table 4.1 Gradient for RP-HPLC analysis of amino acids derivatized with OPA 
Time (min) %B 
0.01 0 
0.5 15 
10 15 
20 45 
27 45 
40 90 
45 90 
 
 For absolute quantitation, five amino acid calibration standards covering the range 50-
250pmol were subjected to hydrolysis conditions, derivatized, and analyzed by RP-HPLC to 
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construct an external calibration curve, with six replicates for each standard.  Peak areas of 14 
components of the Amino Acid Standard H solution were ach normalized against the peak area 
for 150pmol Nva internal standard and plotted against the amount of amino acid in pmol.  Linear 
relationships with R2 ≥ 0.99 were defined for each of these components.  Ala was selected as the 
component of choice for peptide quantitation, due to its stability during hydrolysis, its presence 
in the sequence of all of the model peptides, and its good resolution from the other solution 
components.  The Ala and Nva peaks were identified based on retention times for single-
component authentic standards.  The method was found to be accurate within 6% for most 
nitropeptide standards of known concentration, as measured using absorbance of nitrotyrosine 
with ε356 = 2,910M
-1cm-1 in 0.01N hydrochloric acid (10).  During analysis of peptide samples, 
method performance was checked daily with a standard containing 150pmol AA Standard H and 
150pmol Nva. 
4.3 Results 
4.3.1 Optimal Reaction Conditions 
 In order to minimize side products from the reaction of SDT with nitropeptides, it is 
desirable to use the lowest possible reagent concentratio  and a short reaction time.  In order to 
determine the lowest amount of reagent required to completely reduce 3NY to 3AY in the 
FSAYLER peptide, a range of concentrations was tested and product yield compared by RP-
HPLC analysis.  As shown in Figure 4.3, for 500µM FSA(3NY)LER, reaction with 5mM SDT 
for 1min was sufficient for complete reduction and gave two  products.  Product 1 was identified 
by HPLC-MS/MS as the desired aminopeptide, FSA(3AY)LER (Fig. 4.4a).  Product 2 was also 
characterized by LC-MS/MS (Fig. 4.4b), which suggests that it is the sulfated form of the 
aminopeptide.  Sulfated Tyr is quite labile, readily losing SO3 during the electrospray ionization  
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Fig. 4.3 Optimization of conditions to reduce 3NY to 3AY in FSAYLER.  A range of concentrations of 
sodium dithionite (SDT) were added to 500µM peptide in 120µL total volume. After a reaction time of 
one minute, 100µL of the reduced peptide solution was injected onto RP-HPLC for purification. 
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Fig. 4.4 Mass spectra for reduced FSAYLER, products 1 (a) and 2 (b).  Following reaction of 500µM 
FSA(3NY)LER with 5mM SDT, two products were purified by RP-HPLC, dried in a Centrivap, re-
constituted in 18MΩ water, and analyzed by capillary HPLC-MS. 
FSA(3AY)LER 
[MH+SO
3
]
+
 
MH
+
 
+Na 
y
2
 
y
3
 
y
4
 
y
5
 
y
6
 
[M+2H]
+2
 
FSA(3AY)LER + SO
3
 
y
3
 
[M+2H]
+2
 
y
4
 y5 
y
6
 
MH
+
 
[MH+SO
3
+Na]
+
 
y
2
 
[M+SO
3
+2H]
+2
 
a 
b 
129 
 
process (16) and thus leaving only traces of the intact product observable in the first-dimension 
mass spectrum, together with a significant amount of the non-sulfated aminopeptide. 
 To determine the optimal fluorogenic tagging conditions, a concentration matrix for the 
reagents potassium ferricyanide and APPD was tested wi h 50µM FSA(3AY)LER (estimated 
concentration, assuming 100% yield from reduction reaction).  It has been previously 
demonstrated that this derivatization reaction is particularly sensitive to the potassium 
ferricyanide concentration (9).  As shown in 
Fig. 4.5, based on fluorescent HPLC peak 
area for the desired product, potassium 
ferricyanide concentrations above 250µM (5-
fold molar excess over peptide) and APPD 
concentrations above 10mM (200-fold molar 
excess over peptide) give the highest product 
yield.  In order to limit the formation of side 
products that may occur with excess reagents, 
concentrations at these thresholds were 
selected for the rest of the study.  
4.3.2 Product Isolation and Identification 
 These same conditions were then applied to all five model peptides, and the major 
products were identified by HPLC-MS/MS.  MS/MS data lso confirmed the structures of the 
nitro- and aminopeptides for each model.  For the peptide FSAYYER, note that only the HPLC 
peak containing the peptide with both 3NY residues reduced to 3AY was collected and 
derivatized (peak 1, Fig. 4.6).  The small amount of sulfated product observed by MS is likely 
Fig. 4.5  Dependence of fluorescent HPLC 
peak areas on concentrations of postassium 
ferricyanide and APPD used to derivatize 
50µM FSA(3AY)LER in 50mM ammonium 
bicarbonate, pH 9, for 10min at room 
temperature in the dark. 
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due to incomplete resolution of peaks 1 and 2 by RP-HPLC.  Note that neither of these peaks 
absorb at 356nm, as expected in the absence of 3NY. Conversely, peaks 3 and 4 both show 
absorbance at 356nm (as well as 214nm), indicating that these represent 3NY-containing 
peptides, most likely FSA(3NY)(3AY)ER and FSA(3AY)(3NY)ER in peak 3 and 
FSA(3NY)(3NY)ER in peak 4.  The retention time of peak 4 matches the chromatogram of the 
stock nitropeptide.  Figures 4.7 through 4.11 show the MS/MS spectra for each APPD-labeled 
peptide. 
All five peptides yielded the APPD2-labeled peptide as a major product.  For FSAYYER, 
Fig. 4.6 HPLC and MS of FSAYYER reduction products: (a) chromatogram with UV detection at 214nm 
(b) chromatogram with UV detection at 356nm = λ
max
 for 3NY (c) mass spectrum for peak 1 
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the major product was labeled with APPD2 on both Tyr residues.  Due to the low product yield, 
purified product was collected from five samples and pooled to produce each of three replicate 
samples for further analysis. 
For the calmodulin peptide, three products were observed in nearly equal yield: APPD2 
(Fig. 4.11b) and two cross-link-containing products.  The MS/MS spectra suggest that one is 
cross-linked through the neighboring Lys residue (Fig. 4.11a) and the other is cross-linked 
through the N-terminus (Fig. 4.11c).  As the two intramolecular cross-linked products are 
isobaric, the absence of y ions in particular regions f the peptide sequence is the only evidence 
to distinguish the two structures.  The significant difference in RP-HPLC retention times is likely 
due to differences in peptide surface area properties, and this allows for purification of the two 
products for fluorescence quantum yield measurements (see section 4.3.3) and other analyses.  
The APPD2 product was also well resolved from the other compunds for further 
characterization.  However, since the yield of each individual product was too low for accurate 
analysis, each of the three products was collected from two tagging reactions, and the 
corresponding fractions were pooled.  This process was repeated to give triplicate samples for 
each of the three purified products. 
4.3.3 Fluorescence Quantum Yields and Other Spectroscopic Properties 
 Spectroscopic study of the APPD-labeled peptides revealed some important differences 
among different peptide sequences and especially among the different product structures 
resulting from the calmodulin peptide, as shown in Table 4.2.  Fluorescence quantum yields were 
very similar for APPD2-labeled FSAYLER (0.333), FSAYEER (0.355), and FSAYRER (0.376) 
but almost eight-fold lower for FSAYYER (0.046) labeled with the APPD2-type product at both 
of the adjacent Tyr sites.  All of these labeled peptides have absorption maxima near 372nm and 
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Fig. 4.7 Tandem mass spectrum for FSA(Y-APPD
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Fig. 4.9 Tandem mass spectrum for FSA(Y-APPD
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Fig. 4.10 Tandem mass spectrum for FSA(Y-APPD
2
)(Y-APPD
2
)ER. 
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Fig. 4.11 Tandem mass spectra for APPD-calmodulin peptide products.  The peptide sequence is 
VFDKDGNGYISAAELR.  (a) Product 1: Y-APPD-Lys cross-link (b) Product 2: Y-APPD
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fluorescence emission maxima near 530nm.  The calmodulin peptide, VFDKDGNGYISAAELR, 
labeled with APPD2 (product 2) has similar absorption and emission maxi , although its 
quantum yield is lower (0.250).  However, the two cr ss-linked calmodulin peptide-APPD 
products (products 1 and 3) have the quantum yields, absorption maxima, and fluorescence 
emission maxima that differ both from all of the APPD2-type products and also from each other 
(see Table 4.2). 
4.3.4 Reaction Yields 
 The yield of each reaction step was calculated based on the results of amino acid analysis.  
Where applicable, outliers were excluded at a confide ce level of 90% or higher based on 
Dixon’s Q test (8).  The accuracy of the amino acid analysis method was also evaluated by 
comparison to nitropeptide quantitation by UV-visible spectrometry (Table 4.3).  For all peptides 
except FSA(3NY)EER, for which the raw data indicate significant sample loss during vapor-
phase hydrolysis, the error was less than 6%.  Normalization against the internal Nva standard 
compensated significantly for the low sample recovery in these samples, but working near the 
detection limit nevertheless introduced more variability into the analysis.  Largely due to this 
source of experimental error, the reaction yields for the reduction of 3NY to 3AY by SDT is 
reported based on both the AAA and the UV-visible data for quantitation of the starting material, 
the nitropeptide (Table 4.4).   These yields are similar for all peptide sequences, in the range 48-
63% (using UV-visible data for starting material).  It is likely that the remainder of the starting 
material is converted to the sulfated form of the aminopeptide, as suggested by the HPLC-MS 
data (see Fig 4.4).  In addition, the RP-HPLC chromatograms (see Fig. 4.3 as an example) show 
loss of the nitropeptide peak and nearly equal peak areas for the desired aminopeptide product 
and the putative sulfated aminopeptide side product. 
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Table 4.2 Spectoscopic data for APPD-labeled peptides 
Peptide
Absorbance 
λmax
Fluorescence 
(λem)max A375
Fluorescence 
Area
Reference 
A375
Reference 
Fluorescence 
Area
Fluorescence 
Quantum 
Yield
FSAYLER 372.0 536.0 0.0330 2408.591 0.0331 3582.682 0.330
373.0 533.0 0.0330 2479.055 0.340
370.5 530.4 0.0374 2747.076 0.333
374.0 535.0 0.0377 2749.175 0.330
mean 372.4 533.6 0.0353 2595.974 0.333
standard deviation 1.5 2.5 0.0026 178.031 0.005
FSAYEER 373.0 529.0 0.0552 4359.021 0.0512 5454.080 0.363
373.0 530.6 0.0537 4121.700 0.353
372.5 531.8 0.0545 4148.742 0.350
mean 372.8 530.5 0.0545 4209.821 0.355
standard deviation 0.3 1.4 0.0008 129.917 0.007
FSAYRER 371.0 531.4 0.0716 5609.145 0.0620 6153.151 0.387
372.0 528.4 0.0568 4198.811 0.365
371.0 524.0 0.0660 5030.395 0.376
mean 371.3 527.9 0.0648 4946.117 0.376
standard deviation 0.6 3.7 0.0075 708.934 0.011
FSAYYER 371.0 530.0 0.0177 194.320 0.0161 1946.963 0.044
369.0 527.2 0.0172 204.999 0.048
371.0 529.8 0.0203 230.787 0.046
mean 370.3 529.0 0.0184 210.035 0.046
standard deviation 1.2 1.6 0.0017 18.748 0.002
VFDKDGNGYISAAELR
product 1 373.1 528.2 0.0027 55.171 0.0055 658.162 0.084
367.0 541.4 0.0066 307.429 0.191
373.1 542.4 0.0095 383.109 0.165
mean 371.1 537.3 0.0063 248.570 0.147
standard deviation 3.5 7.9 0.0034 171.709 0.056
product 2 373.1 529.4 0.0098 637.347 0.0104 1247.178 0.266
364.5 527.8 0.0158 868.161 0.225
373.1 530.8 0.0105 664.966 0.259
mean 370.2 529.3 0.0120 723.491 0.250
standard deviation 5.0 1.5 0.0033 126.046 0.022
product 3 363.5 517.2 0.0283 2989.571 0.0257 3073.507 0.433
363.5 514.2 0.0362 3747.316 0.424
363.0 511.4 0.0278 2838.774 0.418
mean 363.3 514.3 0.0308 3191.887 0.425
standard deviation 0.3 2.9 0.0047 486.889 0.007
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Table 4.3 Accuracy of AAA for nitropeptides (relative to UV-is determination) 
Peptide Error 
FSA(3NY)LER 6% 
FSA(3NY)EER 23% 
FSA(3NY)RER 3% 
FSA(3NY)(3NY)ER 4% 
VFDKDGNG(3NY)ISAAELR 6% 
 
Table 4.4 Reduction reaction yields by AAA 
Peptide AAA Yield  UV Yield 
FSA(3AY)LER 53% ±  3% 57% ±  3% 
FSA(3AY)EER 82% ±  4% 63% ±  3% 
FSA(3AY)RER 60% ±  4% 62% ±  4% 
FSA(3AY)(3AY)ER 48% ±  10% 48% ±  10% 
VFDKDGNG(3AY)ISAAELR 52% ±  2% 49% ±  2% 
 
 Three of the peptides showed APPD tagging reaction yields of 35% or better: FSAYLER, 
FSAYEER, and FSAYRER, in order of increasing yield (Table 4.5).  However, FSAYYER and 
all of the calmodulin peptide products showed very low yields, 3-7%.  Some attempts to improve 
the yield of labeled FSAYYER by altering reagent con entrations were unsuccessful (data not 
shown).  These yields reflect not only efficiency of the labeling reaction, but also recovery from 
the purification and re-constitution processes. 
4.3.5 Molar Absorptivities 
 The molar absorptivities, ε of the tagged peptides range from approximately 6,600-
29,000M-1cm-1, as shown in Table 4.5.  Each value was calculated t the wavelength of 
maximum absorption (see Table 4.2).  For the labeled FSAYYER peptide, ε represents the molar 
absorptivity of each individual Y-APPD2 residue.  Peptide sequence and product structure do 
lead to significant differences in ε.  Despite triplicate sample sets for both the taggin  reactions 
and the amino acid analysis, some of the ε values have large standard deviations.  This is 
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particularly the case when product yields are low, specifically for FSAYYER and the calmodulin 
peptide, and thus may be the result of experimental error inherent in measuring samples with 
very low analyte concentration. 
Table 4.5 Tagging yields and molar absorptivities.  *value omitted based on Q-test 
Peptide Yield Concentration (µM) Amax ε (M-1cm-1) 
FSA(Y-APPD
2
)LER 35% ±  23%       
    4.0 ±  0.9 0.0331 8200 
    1.5 ±  0.3 0.0375 24632* 
    4.2 ±  3.2 0.0379 8922 
        mean: 8561 
              st dev: 511 
FSA(Y-APPD
2
)EER 43% ±  3%       
    4.3 ±  0.05 0.0554 12878 
    4.1 ±  0.3 0.0538 13197 
    4.2 ±  0.5 0.0546 12863 
        mean: 12979 
              st dev: 188 
FSA(Y-APPD
2
)RER 70% ±  5%       
    6.6 ±  0.2 0.0719 10851 
    7.6 ±  0.4 0.0572 7480 
    7.6 ±  0.3 0.0663 8721 
        mean: 9017 
              st dev: 1705 
FSA(Y-APPD
2
)(Y-APPD
2
)ER 3% ±  1%       
    0.39 ±  0.01 0.0180 23339 
    0.67 ±  0.28 0.0175 13053 
    0.91 ±  0.43 0.0207 11335 
        mean: 15909 
              st dev: 6492 
VFD(K-)DGNG(-Y-APPD)ISAAELR 6% ±  3%       
    0.56 ±  0.05 0.0028 5028 
    1.00 ±  0.44 0.0068 6783 
    1.22 ±  0.56 0.0097 7941 
        mean: 6584 
              st dev: 1467 
VFDKDGNG(Y-APPD
2
)ISAAELR 5% ±  2%       
    0.61 ±  0.09 0.0101 16502 
    1.06 ±  0.28 0.0166 15697 
    0.79 ±  0.39 0.0107 13466 
        mean: 15222 
              st dev: 1573 
(-NH)VFDKDGNG(-Y-APPD)ISAAELR 7% ±  1%       
    1.08 ±  0.08 0.0307 28345 
    1.32 ±  0.02 0.0397 30152 
    1.06 ±  0.04 0.0300 28306 
        mean: 28934 
        st dev: 1055 
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4.4 Discussion and Conclusions 
 A major challenge of proteomic analysis is the wide diversity of targets in every sample, 
with the goal being the identification (and, ultimately, quantitation) of each one without bias.  
Moreover, analysis of low-abundance post-translation l modifications like 3NY and DOPA 
makes full labeling and sequence coverage especially rucial.  Therefore, it is important to 
understand how derivatization reactions and their products behave with peptide targets 
possessing a range of physicochemical properties. 
 In the present study, the reduction of 3NY to 3AY by SDT showed little dependence on 
peptide sequence.  On the other hand, the efficiency of the tagging reaction and the spectroscopic 
properties of the products showed significant variation.  Peptides with the sequence FSAYXER 
displayed similar behavior, except when a second 3NY residue was introduced adjacent to the 
original one.  The FSAYYER peptide showed very low product yield, which may result not only 
from poor chemical yield but also from solubility limitations.  The APPD moieties add 
significant hydrophobic character to any labeled peptid , as evidenced by long RP-HPLC 
retention times, and introducing APPD2 labels at two adjacent amino acid residues would be 
expected to greatly reduce the solubility of labeled p ptide in water.  Indeed, fluorescent residue 
was observed by eye in the quartz collection tubes upon examination under a UV lamp after 
reconstituting the labeled peptide and transferring it to a clean container.  The fluorescence 
quantum yield for APPD-labeled FSAYYER was also extr mely low.  This may be the result of 
fluorescence quenching or some other physicochemical and/or electronic interaction between the 
adjacent fluorophores. 
 The calmodulin peptide is an interesting case because it provides an opportunity to 
compare three different product structures.  While ch mical yields were similar for each of the 
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three products, they differed in RP-HPLC retention mes, absorption and emission maxima, 
fluorescence quantum yields, and molar absorptivities.  Notably, even the isobaric amine-Tyr 
cross-linked products (products 1 and 3) were significantly different from each other in all of 
these areas.  The only difference between these structures is the location of the amine, whether 
on the nearby Lys (product 1) or the N-terminus (product 3).  While chemically very similar, it is 
reasonable to expect that properties of stereochemistry and dynamics could be significantly 
different and consequently produce differences in the quantum physical and electronic properties 
of the compounds. 
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Chapter 5: Conclusions and Future Directions
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5.1  Summary and Conclusions 
The goal of this dissertation project was to develop and apply a novel derivatization 
method for labeling 3-nitrotyrosine (3NY) and 3,4-dihydroxyphenylalanine (DOPA) in order to 
facilitate proteomic studies of these oxidative post-translational modifications in cardiac tissue 
from a rat model of aging.  Benzylamine (BA) reacts with DOPA and 3AY (formed from 3NY 
by reduction with sodium dithionite, SDT) in the presence of the oxidant potassium ferricyanide 
to give fluorescent 2-phenylbenzoxazole products.  Two substituted benzylamine reagents have 
also been synthesized and applied in this method: 4-(aminomethyl)benzenesulfonic acid (ABS) 
and (3R,4S)-1-(4-(aminomethyl)phenylsulfonyl)pyrrolidine-3,4-diol (APPD). 
This method had previously been developed with model compounds, ranging from small 
molecules to peptides to purified proteins (1,2), and the task of translating it to a complex 
biological sample, like cardiac homogenate, is not trivial.  By nature, proteomic studies aim to 
detect, identify, and quantify not a single analyte, but hundreds (or more).  Each of these analytes 
may respond differently to sample preparation steps and particularly to the derivatization 
chemistry, as demonstrated with a series of model peptides (Chapter 4).  Moreover, the 
biological matrix often contains reactive or otherwise interfering species, and the use of protein-
stabilizing solution additives, like detergents and re ucing agents, can further complicate 
analysis.  One manifestation of this problem is the loss of 3NY from the model protein glycogen 
phosphorylase b (Ph-b) upon mixing with cardiac homogenate (Chapter 3).  Cleaning steps to 
remove interfering species, excess reagents, and side products after each step in the method are 
necessary but open the door for significant sample losses and experimental bias, as explored in 
Chapters 2 and 3.  Finally, bottom-up proteomic identifications rely upon matching tandem mass 
spectrometry (MS/MS) spectra from complex samples of tryptic peptides to database information 
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on theoretical fragmentation patterns for known protein sequences in the proteome of the species 
under study.  Given the likelihood of false identification, stringent criteria must be applied for 
confident identifications.  Moreover, assignment of an identified modification (e.g., +45amu for 
nitration) to a particular residue in the peptide (e.g., Tyr) is best evidenced when peptide bond 
cleavage occurs on both sides of the modified residu  during collision-induced dissociation in 
the mass spectrometer.  Meeting all of these criteria r quires sufficient signal-to-noise ratio in 
mass spectrometric experiments, which is particularly difficult to achieve for low-abundance 
species like 3NY and DOPA in the presence of an overwh lming matrix of other, non-modified 
cardiac peptides. 
In response to these challenges, many aspects of the sample preparation and 
derivatization procedures were optimized, using both cardiac homogenates and model systems.  
By size-exclusion high-performance liquid chromatography (SE-HPLC), calibrated with protein 
molecular-weight standards, it was demonstrated that the fluorescent products in cardiac samples 
were indeed labeled proteins.  In several experiments, a significant difference in fluorescence 
intensity was observed for samples that were reduced with SDT compared to those that were not.  
Since 3NY, but not DOPA, requires this reduction step for labeling, this difference can be 
attributed to the presence of 3NY.  Indeed, for the model protein Ph-b nitrated in vitro with 
peroxynitrite and mixed with cardiac proteins, the fluorescence intensity showed a linear 
dependence on the amount of 3NY (as determined by UV-visible absorbance measurements of 
the pure, nitrated protein).  For cardiac proteins, the comparison of reduced and non-reduced 
samples did not always give consistent results.  Similarly, comparisons of cardiac homogenates 
from old and young rats did not give consistent results regarding age-dependency of 3NY or 
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DOPA levels.  This variability may be due to 3NY levels below the limit of detection, changes in 
experimental conditions that can affect labeling, and/or animal-to-animal variations. 
 For systematic study of labeling properties for different analytes, the method was applied 
to a series of model nitro-peptides with varying sequences.  While changing the acid-base 
properties of a single residue adjacent to 3NY did not significantly affect labeling efficiency, 
fluorescence quantum yield, wavelengths of fluorescence maxima, or molar absorptivity, other 
sequence changes had dramatic effects.  The placement of a second 3NY residue adjacent to the 
first resulted in very low product yield and very small fluorescence quantum yield.  A longer 
peptide with a completely unrelated amino acid sequence formed three distinct fluorescent 
products upon labeling, each with their own chemical yields and spectroscopic properties.  
Importantly, intramolecular cross-links formed in this peptide between the labeled Tyr and either 
the nearby Lys ε-amino group or the N-terminal amino group. 
5.2  Future Directions 
 Nitration of cardiac proteins in vitro should provide a more robust system to finalize 
optimal reaction conditions and investigate the inconsistencies observed for comparisons of 
reduced and non-reduced samples and of old and young rat tissues.  The role of protein 
precipitation protocols can also be more thoroughly evaluated with these samples.  By mixing 
nitrated cardiac proteins with untreated ones at varying ratios, a calibration curve could be 
constructed for cardiac proteins, similar to that bsed on nitrated Ph-b.  Using the information 
gained with this model system, the next step is to subject samples containing only endogenous 
DOPA and 3NY to the optimized labeling protocol, folowed by mass spectrometry analysis in 
order to identify sites carrying the benzoxazole labe .  Other tools to improve the chances for 
success in this goal include APPD labeling followed by boronate-affinity HPLC for enrichment 
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of labeled analytes and ultra-high-performance liquid chromatography with mass spectrometry 
for improvement of column capacity and resolution.  Both of these strategies should mitigate ion 
suppression and other interferences from the large number non-modified peptides in the cardiac 
samples. 
 Further information can also be gained from model systems.  For instance, another 
calibration curve for labeled 3NY-Ph-b in a mixture of cardiac proteins could be constructed 
based on SE-HPLC fluorescent peak area of the Ph-b peak. This separation, though crude, could 
improve the assay’s limit of detection.  Model peptides labeled with each of the three 
benzylamine-type reagents can provide insights into characteristic fragments that may form by 
gas-phase reactions in the mass spectrometer.  As long as these fragmentations remain unknown, 
if they exist, the proteomic search algorithms will be unable to find labeled peptides.  The same 
is true for any side products that may form during derivatization, which may or may not be 
fluorescent. 
 As an extension of the model peptide series, more peptide sequences could be tested, 
particularly to focus on the effect of secondary stucture on labeling efficiency and spectroscopic 
properties.  The accessibility of Tyr residues can be an important parameter for derivatization 
yield, and the interactions that contribute to secondary structure could alter the fluorescent and 
absorption properties of labeled Tyr.  For further investigation of primary structure effects, 
variations in the distance between 3NY and Lys or the N-terminus could identify the preferred 
conditions for generating intramolecular cross-links during fluorogenic derivatization. 
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